Cronos (CRON) 10-Q 6 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Aug. 05, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-38403
Entity Registrant Name	CRONOS GROUP INC.
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	111 Peter St. Suite 300
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	M5V 2H1
City Area Code	416
Local Phone Number	504-0004
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	CRON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		371,805,547
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001656472
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents		$ 895,181	$ 1,078,023
Short-term investments		201,699	211,766
Accounts receivable, net		11,299	8,928
Other receivables		2,468	10,033
Current portion of loans receivable, net		5,028	7,083
Prepaids and other current assets		10,153	11,161
Inventory, net		35,605	44,002
Held-for-sale assets		645	1,176
Total current assets		1,162,078	1,372,172
Advances to joint ventures		499	467
Investments in equity accounted investees, net		20,970	19,235
Other investments		110,392	0
Loan receivable, net		94,113	87,191
Property, plant and equipment, net		193,920	187,599
Right-of-use assets		6,687	9,776
Intangible assets, net		70,409	69,720
Goodwill		179,543	179,522
Total assets		1,838,611	1,925,682
Current liabilities
Accounts payable and other liabilities		29,829	42,102
Current portion of lease obligation		1,206	1,322
Derivative liabilities		169,563	163,410
Total current liabilities		200,598	206,834
Due to non-controlling interests		1,768	2,188
Lease obligation		6,333	8,492
Total liabilities		208,699	217,514
Commitments and contingencies
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Share capital	[1],[2]	572,858	569,260
Additional paid-in capital		32,368	34,596
Retained earnings		955,721	1,064,509
Accumulated other comprehensive income		71,729	42,999
Total equity attributable to shareholders of Cronos Group		1,632,676	1,711,364
Non-controlling interests		(2,764)	(3,196)
Total shareholders’ equity		1,629,912	1,708,168
Total liabilities and shareholders’ equity		$ 1,838,611	$ 1,925,682
[1]	Authorized for issuance as of June 30, 2021: unlimited and December 31, 2020: unlimited.
[2]	Shares issued as of June 30, 2021: 371,805,547 and December 31, 2020: 360,253,332.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheet (Parenthetical) - shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	371,805,547	360,253,332

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Net revenue, before excise taxes	$ 18,848,000	$ 11,432,000	$ 33,502,000	$ 20,776,000
Excise taxes	(3,226,000)	(1,549,000)	(5,269,000)	(2,461,000)
Net revenue	15,622,000	9,883,000	28,233,000	18,315,000
Cost of sales	19,445,000	9,743,000	35,019,000	16,689,000
Inventory write-down	11,961,000	3,062,000	11,961,000	11,024,000
Gross loss	(15,784,000)	(2,922,000)	(18,747,000)	(9,398,000)
Operating expenses
Sales and marketing	13,209,000	6,501,000	23,463,000	13,613,000
Research and development (“R&D”)	5,199,000	3,631,000	10,301,000	8,221,000
General and administrative	22,417,000	18,429,000	44,323,000	42,188,000
Share-based payments	2,565,000	2,546,000	5,064,000	4,982,000
Depreciation and amortization	1,043,000	679,000	1,778,000	1,366,000
Total operating expenses	44,433,000	31,786,000	84,929,000	70,370,000
Operating loss	(60,217,000)	(34,708,000)	(103,676,000)	(79,768,000)
Other income (loss)
Interest income, net	2,293,000	3,734,000	4,622,000	11,485,000
Gain (loss) on revaluation of derivative liabilities	115,248,000	(35,880,000)	(1,626,000)	77,488,000
Impairment loss on long-lived assets	0	(40,000,000)	(1,741,000)	(40,000,000)
Share of loss from equity accounted investments	(1,115,000)	(794,000)	(2,758,000)	(1,966,000)
Other, net	1,127,000	(9,000)	911,000	785,000
Total other income (loss)	117,553,000	(72,949,000)	(592,000)	47,792,000
Income (loss) from continuing operations	57,336,000	(107,657,000)	(104,268,000)	(31,976,000)
Loss from discontinued operations	(561,000)	(46,000)	(582,000)	(46,000)
Net income (loss)	56,775,000	(107,703,000)	(104,850,000)	(32,022,000)
Net loss attributable to non-controlling interest	(279,000)	(726,000)	(592,000)	(1,085,000)
Net income (loss) attributable to Cronos Group	57,054,000	(106,977,000)	(104,258,000)	(30,937,000)
Statement of Comprehensive Income [Abstract]
Net income (loss)	56,775,000	(107,703,000)	(104,850,000)	(32,022,000)
Other comprehensive income (loss)
Foreign exchange gain (loss) on translation	13,470,000	51,871,000	29,754,000	(61,821,000)
Total other comprehensive income (loss)	13,470,000	51,871,000	29,754,000	(61,821,000)
Comprehensive income (loss)	70,245,000	(55,832,000)	(75,096,000)	(93,843,000)
Less: comprehensive income (loss) attributable to non-controlling interests	(394,000)	(762,000)	432,000	(1,098,000)
Cronos Group	$ 70,639,000	$ (55,070,000)	$ (75,528,000)	$ (92,745,000)
Net income (loss) per share
Basic - continuing operations (in dollars per share)	$ 0.15	$ (0.31)	$ (0.28)	$ (0.09)
Diluted - continuing operations (in dollars per share)	$ 0.15	$ (0.31)	$ (0.28)	$ (0.09)
Weighted average number of outstanding shares
Basic (in shares)	371,721,382	349,075,408	367,391,118	348,946,439
Diluted (in shares)	375,349,856	349,075,408	367,391,118	348,946,439

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Share capital	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non-controlling interests
Beginning balance (in shares) at Dec. 31, 2019		348,817,472
Beginning balance at Dec. 31, 2019	$ 1,749,030	$ 561,165	$ 23,234	$ 1,137,646	$ 27,838	$ (853)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of options	$ 3,500		3,500
Options exercised (in shares)	1,807,909	1,068,930
Options exercised	$ 1	$ 1,329	(1,328)
Vesting of restricted share units	1,482		1,482
Vesting of common shares issued in connection with the use of certain publicity rights in brand development	2,158	2,000	158
Top-up rights exercised	717	$ 717
Net income (loss)	(32,022)			(30,937)		(1,085)
Foreign exchange gain (loss) on translation	(61,821)				(61,808)	(13)
Ending balance (in shares) at Jun. 30, 2020		349,886,402
Ending balance at Jun. 30, 2020	1,663,045	$ 565,211	27,046	1,106,709	(33,970)	(1,951)
Beginning balance (in shares) at Mar. 31, 2020		348,817,472
Beginning balance at Mar. 31, 2020	1,715,268	$ 563,165	25,483	1,213,686	(85,877)	(1,189)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of options	1,770		1,770
Options exercised (in shares)		1,068,930
Options exercised	1	$ 1,329	(1,328)
Vesting of restricted share units	776		776
Vesting of common shares issued in connection with the use of certain publicity rights in brand development	345		345
Top-up rights exercised	717	$ 717
Net income (loss)	(107,703)			(106,977)		(726)
Foreign exchange gain (loss) on translation	51,871				51,907	(36)
Ending balance (in shares) at Jun. 30, 2020		349,886,402
Ending balance at Jun. 30, 2020	1,663,045	$ 565,211	27,046	1,106,709	(33,970)	(1,951)
Beginning balance (in shares) at Dec. 31, 2020		360,253,332
Beginning balance at Dec. 31, 2020	1,708,168	$ 569,260	34,596	1,064,509	42,999	(3,196)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Warrants exercised (in shares)		7,842,859
Warrants exercised	2	$ 1,165	(1,163)
Vesting of options	$ 3,928		3,928
Options exercised (in shares)	5,349,818	3,651,002
Options exercised	$ 10	$ 3,315	(3,305)
Restricted share units settled (in shares)		58,354
Restricted share units settled	0	$ 345	(345)
Withholding taxes paid on share-based awards	(8,919)		(1,162)	(7,757)
Vesting of restricted share units	1,136		1,136
Vesting of common shares issued in connection with the use of certain publicity rights in brand development	683	2,000	(1,317)
Top-up rights out-of-period adjustment	0	$ (3,227)		3,227
Net income (loss)	(104,850)			(104,258)		(592)
Foreign exchange gain (loss) on translation	29,754				28,730	1,024
Ending balance (in shares) at Jun. 30, 2021		371,805,547
Ending balance at Jun. 30, 2021	1,629,912	$ 572,858	32,368	955,721	71,729	(2,764)
Beginning balance (in shares) at Mar. 31, 2021		371,656,590
Beginning balance at Mar. 31, 2021	1,568,279	$ 584,912	32,090	895,503	58,144	(2,370)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Warrants exercised (in shares)		10,000
Warrants exercised	2	$ 4	(2)
Vesting of options	1,864		1,864
Options exercised (in shares)		80,603
Options exercised	0	$ 102	(102)
Restricted share units settled (in shares)		58,354
Restricted share units settled	0	$ 345	(345)
Withholding taxes paid on share-based awards	(246)		(183)	(63)
Vesting of restricted share units	701		701
Vesting of common shares issued in connection with the use of certain publicity rights in brand development	345	2,000	(1,655)
Top-up rights out-of-period adjustment	(11,278)	$ (14,505)		3,227
Net income (loss)	56,775			57,054		(279)
Foreign exchange gain (loss) on translation	13,470				13,585	(115)
Ending balance (in shares) at Jun. 30, 2021		371,805,547
Ending balance at Jun. 30, 2021	$ 1,629,912	$ 572,858	$ 32,368	$ 955,721	$ 71,729	$ (2,764)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Operating activities
Net income (loss)	$ 56,775	$ (107,703)	$ (104,850)	$ (32,022)
Adjustments to reconcile net loss to cash provided by operating activities:
Share-based payments			5,064	4,982
Depreciation and amortization	3,203	1,717	5,083	2,879
Share of loss from investments in equity accounted investees	1,115	794	2,758	1,966
Gain (loss) on revaluation of derivative liabilities	(115,248)	35,880	1,626	(77,488)
Impairment loss on long-lived assets	0	40,000	1,741	40,000
Expected credit losses on long-term financial assets			0	1,357
Other non-cash operating activities, net			(1,192)	599
Changes in operating assets and liabilities:
Accounts receivable, net			(2,194)	2,895
Other receivables			6,960	(3,047)
Prepaids and other current assets			1,268	1,187
Inventory, net			(1,010)	(24,292)
Inventory write-down	11,961	3,062	11,961	11,024
Accounts payable and other liabilities			(13,412)	(8,417)
Cash flows used in operating activities			(86,197)	(78,377)
Investing activities
Purchase of short-term investments			(120,180)	(200,173)
Proceeds from short-term investments			136,204	279,275
Purchase of other investments			(110,392)	0
Purchase of property, plant and equipment			(8,347)	(13,344)
Purchase of intangible assets			(843)	(2,754)
Proceeds from sale of held-for-sale assets			2,059	0
Advances on loans receivable			(5,064)	(23,974)
Proceeds from sale of other investments			0	769
Cash flows provided by (used in) investing activities			(106,563)	39,799
Financing activities
Withholding taxes paid on share-based awards			(8,919)	0
Proceeds from exercise of warrants and options			12	1
Cash flows provided by (used in) financing activities			(8,907)	1
Effect of foreign currency translation on cash and cash equivalents			18,825	(51,416)
Net change in cash and cash equivalents			(182,842)	(89,993)
Cash and cash equivalents, beginning of period			1,078,023	1,199,693	$ 1,199,693
Cash and cash equivalents, end of period	$ 895,181	$ 1,109,700	895,181	1,109,700	$ 1,078,023
Supplemental cash flow information
Interest paid			0	90
Interest received			2,961	11,575
Income taxes paid			$ 858	$ 0

Background, Basis of Presentati

Background, Basis of Presentation and Accounting Policies	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background, Basis of Presentation and Accounting Policies	Background, Basis of Presentation and Accounting Policies (a) Background Cronos Group Inc. (“Cronos Group” or the “Company”) is incorporated in the Province of British Columbia and under the Business Corporations Act (British Columbia) with principal executive offices at 111 Peter Street, Suite 300, Toronto, Ontario, M5V 2H1. The Company’s common shares are currently listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.” Cronos Group is an innovative global cannabinoid company, with international production and distribution across five continents. The Company is committed to building disruptive intellectual property by advancing cannabis research, technology and product development and is seeking to build an iconic brand portfolio. Cronos Group’s brand portfolio includes PEACE NATURALS ™ , a global wellness platform; two adult-use brands, COVE ™ and Spinach ™ ; and three U.S. hemp-derived consumer products brands, Lord Jones ™ , Happy Dance ™ and PEACE+ ™ . Cronos Group has established strategic joint ventures in Canada, Israel, and Colombia. “Cronos Israel” consists of a cultivation company (Cronos Israel G.S. Cultivation Ltd.), a manufacturing company (Cronos Israel G.S. Manufacturing Ltd.), a distribution company (Cronos Israel G.S. Store Ltd.) and a pharmacy company (Cronos Israel G.S. Pharmacy Ltd.) and is consolidated for financial reporting purposes. The Company also holds approximately 31% of the issued capital of Cronos Australia Limited (“Cronos Australia”) and accounts for its investment in Cronos Australia under the equity method of accounting. For additional discussion regarding the joint ventures and strategic investment, see Note 3. Investments. (b) Out-of-period adjustments During the three months ended March 31, 2021, the Company identified an error in the accounting related to the withholding taxes on the net exercise of stock options, which resulted in an understatement of accounts payable and other liabilities of $966 and overstatements of other receivables, retained earnings and share capital of $3,202, $3,838 and $330, respectively, as of December 31, 2020. The error was deemed immaterial, and thus the Company has recorded an out-of-period adjustment to the condensed consolidated balance sheet and the condensed consolidated statement of changes in equity during the first quarter of 2021 to correct the error. This error had no impact to the condensed consolidated statement of net income (loss) and comprehensive income (loss). The impact of the out-of-period adjustments are included within the changes in operating assets and liabilities and withholding taxes paid on share-based awards lines in the Company’s condensed consolidated statements of cash flows. During the three months ended June 30, 2021, the Company identified an error in the accounting related to the exercise of Top-up Rights (as defined herein), which resulted in an overstatement of share capital and an understatement of gain on revaluation of derivative liabilities of $3,227 as of December 31, 2020, and overstatements of share capital and loss on revaluation of derivative liabilities and an understatement of retained earnings of $14,505, $11,278 and $3,227, respectively, as of March 31, 2021. The error was deemed immaterial, and thus the Company has recorded an out-of-period adjustment to the condensed consolidated balance sheet, the condensed consolidated statement of net income (loss) and comprehensive income (loss) and the condensed consolidated statement of changes in equity during the second quarter of 2021 to correct the error. The impact of the out-of-period adjustments are included within the adjustments to net loss in the Company’s condensed consolidated statements of cash flows. (c) Basis of presentation The interim condensed consolidated financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2020 (the “Annual Financial Statements”). Certain prior year amounts have been reclassified to conform to the current year presentation of our condensed consolidated financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity. (d) Adoption of new accounting pronouncements On January 1, 2021, the Company adopted ASU No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU No. 2020-01”). ASU No. 2020-01 clarifies the interaction of accounting for the transition into and out of the equity method as well as measuring certain purchased options and forward contracts to acquire investments. The adoption of ASU No. 2020-01 did not have an impact on the Company’s interim condensed consolidated financial statements. On January 1, 2021, the Company adopted ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU No. 2019-12”). ASU No. 2019-12 eliminates certain exceptions and simplifies the application of U.S. GAAP-related changes in enacted tax laws or rates and employee stock option plans. The adoption of ASU No. 2019-12 did not have an impact on the Company’s interim condensed consolidated financial statements. (e) New accounting pronouncements not yet adopted In August 2020, the FASB issued ASU 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815–40) (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU No. 2020-06 is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU No. 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU No. 2020-06 will have on its condensed consolidated financial statements.

Inventory, net

Inventory, net	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventory, net	Inventory, net Inventory, net is comprised of the following items: As of June 30, 2021 As of December 31, 2020 Raw materials $ 7,471 $ 11,489 Work-in-progress 17,291 26,278 Finished goods 10,247 5,905 Supplies and consumables 596 330 Total $ 35,605 $ 44,002 Inventory is written down for any obsolescence such as slow-moving or non-marketable products, or when the net realizable value of inventory is less than the carrying value. During the three months ended June 30, 2021 and 2020, the Company recorded write-downs related to inventory of $11,961 and $3,062, respectively. During the six months ended June 30, 2021 and 2020, the Company recorded write-downs related to inventory of $11,961 and $11,024, respectively.

Investments

Investments	6 Months Ended
	Jun. 30, 2021
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments (a) Variable interest entities and investments in equity accounted investees, net The Company holds variable interests in Cronos Growing Company Inc. (“Cronos GrowCo”), Natuera S.à.r.l (“Natuera”), MedMen Canada Inc. (“MedMen Canada”) and Cannasoul Lab Services Ltd. (“CLS”). The Company’s investments in Cronos GrowCo, Natuera and MedMen Canada are exposed to economic variability from each entity’s performance; however, the Company does not consolidate the entities as it does not have the power to direct the activities that most significantly impact each entity’s economic performance. Thus, Cronos Group is not considered the primary beneficiary of each entity. These investments are accounted for as equity method investments classified as “Investments in equity accounted investees, net” in the consolidated balance sheets. Cronos GrowCo is a joint venture incorporated under the Canada Business Corporations Act (“CBCA”) on June 14, 2018 with the objective of cultivating and commercializing cannabis and cannabis products. Cronos Group holds variable interests in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt. Cronos GrowCo’s economic performance is driven by the quantity and strains of cannabis grown. The joint venture partners mutually determine the quantity and strains of cannabis grown. MedMen Canada is a joint venture incorporated under the CBCA on March 13, 2018, with the objective of the retail sale and marketing of cannabis products in Canada. MedMen Canada holds the exclusive license to the MedMen brand in Canada for a minimum term of 20 years. The Company holds variable interests in MedMen Canada through its ownership of 50% of MedMen Canada’s common shares and other subordinated debt. MedMen Canada’s economic performance is driven by the quantity and strains of cannabis sold. Subject to applicable law, the joint venture partners mutually determine the quantity and strains of cannabis to be sold in MedMen Canada’s retail stores, if and when stores are opened. Natuera is a joint venture registered in Luxembourg with the objective of cultivating and commercializing hemp and cannabis products. The Company holds variable interests in Natuera through its ownership of 50% of Natuera’s common shares. Natuera’s economic performance is driven by the quantity and strains of cannabis grown, which is mutually determined by the joint venture partners. CLS is a wholly owned subsidiary of Cannasoul Analytics Ltd., incorporated with the purpose of establishing a commercial cannabis analytical testing laboratory located on the premises of Cronos Israel (the “Cannasoul Collaboration”). Cronos Israel agreed to advance up to ILS 8,297 ($2,511) by a non-recourse loan (the “Cannasoul Collaboration Loan”) to CLS over a period of two years from April 1, 2020 for the capital and operating expenditures of the laboratory. The loan bears interest at 3.5% annually. Cronos Israel will receive 70% of the profits of the laboratory until such time as it has recovered 150% of the amounts advanced to CLS, after which time it will receive 50% of the laboratory profits. As a result, the Company is exposed to economic variability from CLS’s performance. The Company does not consolidate CLS as it does not have the power to direct the activities that most significantly impact the entity’s economic performance; thus, the Company is not considered the primary beneficiary of the entity. The carrying amount of the non-recourse loan is recorded under loans receivable and the full loan amount, ILS 8,297, represents the Company’s maximum potential exposure to losses through the Cannasoul Collaboration. See Note 4. Loans Receivable, net for further information regarding loans receivable. A reconciliation of the carrying amount of the investments in associates and joint ventures is as follows: Ownership interest As of June 30, 2021 As of December 31, 2020 Cronos Australia 31% $ — $ — Cronos GrowCo 50% 19,022 19,235 Natuera (i) 50% 1,948 — $ 20,970 $ 19,235 (i) On April 1, 2021, the Company and an affiliate of Agroidea (“AGI”), the other joint venture partner of Natuera, converted all advances made to Natuera under the master loan agreement entered into with Natuera on September 27, 2019 (the “Natuera Series A Loan”), plus accrued interest, into equity of Natuera. Total aggregate gross advances to Natuera under the Natuera Series A Loan were $15,500, of which the Company advanced 50% and AGI advanced the remaining 50%, or $7,750 each. As a result, the Company transferred the carrying value of the Natuera Series A Loan of approximately $2,013 plus accrued interest of $540, for a total investment value of $2,553, which approximates fair value, to investments in equity accounted investees in respect of Natuera. See Note 4. Loans Receivable, net. The Company’s share of net losses from equity investments accounted for under the equity method of accounting: For the three months ended June 30, For the six months ended June 30, 2021 2020 2021 2020 Cronos Australia $ — $ (235) $ — $ (235) Cronos GrowCo (459) (190) (758) (501) Natuera (656) (369) (2,000) (1,230) $ (1,115) $ (794) $ (2,758) $ (1,966) The Company determined that the maximum exposure of loss on investments in non-consolidated investments is limited to the Company’s initial investment, advances and/or loans for each variable interest entity. The following is a summary of the maximum exposure to loss as of June 30, 2021 and December 31, 2020: Ownership interest As of June 30, 2021 As of December 31, 2020 Cronos Australia 31% $ 1,573 $ 1,530 Cronos GrowCo 50% 21,723 21,125 MedMen Canada 50% 494 467 Natuera 50% 8,047 8,154 Total $ 31,837 $ 31,276 (b) Other investments Other investments consist of investments in options of companies in the cannabis industry. On June 14, 2021, the Company purchased an option to acquire 473,787 shares of Class A Common Stock of PharmaCann, Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis, for an aggregate purchase price of approximately $110,392. The option exercise will be based upon various factors, including the status of U.S. federal cannabis legalization, as well as regulatory approvals, including in the states where PharmaCann operates that may be required upon exercise. This option is classified as an equity security without a readily determinable fair value. The Company has elected to measure the fair value of the option at cost less impairment, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The option is reported as other investments on the condensed consolidated balance sheet for the period ended June 30, 2021. As of June 30, 2021 and December 31, 2020, the Company did not hold any additional other investments.

Loans Receivable, net

Loans Receivable, net	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Loans Receivable, net	Loans Receivable, net As of June 30, 2021 As of December 31, 2020 Natuera Series A Loan (i) $ — $ 3,518 GrowCo Facility (ii) 1,614 3,137 Add: Accrued interest 3,414 428 Total current portion of loans receivable 5,028 7,083 GrowCo Facility (ii) 77,474 69,939 Mucci Promissory Note (iii) 13,969 13,324 Cannasoul Collaboration Loan (iv) 1,870 1,261 Add: Accrued interest 800 2,667 Total long-term portion of loans receivable 94,113 87,191 Total loans receivable, net $ 99,141 $ 94,274 (i) On April 1, 2021, the Company and AGI converted all advances made to Natuera under the Series A Loan, plus accrued interest, into equity of Natuera. Total aggregate gross advances to Natuera under the Natuera Series A Loan were $15,500, of which the Company advanced 50% and AGI advanced the remaining 50%, or $7,750 each. As a result, the Company transferred the carrying value of the Natuera Series A Loan of approximately $2,013 plus accrued interest of $540, for a total investment value of $2,553, which approximates fair value, to investments in equity accounted investees in respect of Natuera. See Note 3. Investments. (ii) As of June 30, 2021 and December 31, 2020, Cronos GrowCo had drawn C$100,000 ($80,678) and C$95,150 ($74,626), respectively, from a credit agreement it entered into with the Company in August 2019 (the “GrowCo Facility”). As of June 30, 2021 and December 31, 2020, the Company had an allowance for credit losses of $1,590 and $1,470, respectively, recorded against the GrowCo Facility. (iii) As of June 30, 2021 and December 31, 2020, the Company had an allowance for credit losses of $278 and $259, respectively, recorded against the promissory note receivable agreement entered into with Mucci on June 28, 2019 (the “Mucci Promissory Note”). (iv) As of June 30, 2021 and December 31, 2020 CLS has received ILS 6,223 and ILS 4,149 (approximately $1,909 and $1,287 respectively) from the Cannasoul Collaboration Loan. As of June 30, 2021 and December 31, 2020, the Company had an allowance for credit losses of $39 and $25, respectively, recorded against the Cannasoul Collaboration Loan.

Derivative Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Derivative Liabilities On March 8, 2019, the Company closed the previously announced investment in the Company (the “Altria Investment”) by Altria Group, Inc. (“Altria”), pursuant to a subscription agreement dated December 7, 2018. As of the closing date of the Altria Investment, the Altria Investment consisted of 149,831,154 common shares of the Company and one warrant of the Company (the “Altria Warrant”), all of which were issued to a wholly owned subsidiary of Altria. As of the closing date of the Altria Investment, Altria beneficially held an approximately 45% ownership interest in the Company (calculated on a non-diluted basis). As summarized in this note, if exercised in full on such date, the exercise of the Altria Warrant would have resulted in Altria holding a total ownership interest in the Company of approximately 55% (calculated on a non-diluted basis). As of June 30, 2021, Altria beneficially held an approximately 42% ownership interest in the Company (calculated on a non-diluted basis). As summarized in this note, if exercised in full on such date, the exercise of the Altria Warrant would have resulted in Altria holding a total ownership interest in the Company of approximately 53% (calculated on a non-diluted basis). Pursuant to the investor rights agreement between the Company and Altria, entered into in connection with the closing of the Altria Investment (the “Investor Rights Agreement”), the Company granted Altria certain rights, among others, summarized in this note. The summaries below are qualified entirely by the terms and conditions fully set out in the Investor Rights Agreement and the Altria Warrant, as applicable. a. The Altria Warrant entitles the holder, subject to certain qualifications and limitations, to subscribe for and purchase up to an additional approximate 10% of the common shares of Cronos (approximately 83 million common shares at June 30, 2021) at a per share exercise price of C$19.00, which expires on March 8, 2023. b. The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the R&D partnership with Ginkgo Bioworks Inc. (“Ginkgo”) (the “Ginkgo Strategic Partnership”)), the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any issuance of shares by the Company (“Pre-emptive Rights”), at the same price per common share of the Company at which the common shares are sold in the relevant issuance. The price per common share of the Company to be paid by Altria pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo Strategic Partnership will be C$16.25 per common share. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. c. In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter (excluding any convertible securities of the Company owned by Altria or any of its subsidiaries), a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplate an equity component or bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions (“Top-up Rights”). The price per common share to be paid by Altria pursuant to the exercise of its Top-up Rights will be, subject to certain limited exceptions, the 10-day volume-weighted average price of the common shares of the Company on the TSX for the ten full days preceding such exercise by Altria, provided that the price per common share of the Company to be paid by Altria pursuant to the exercise of its Top-up Rights in connection with the issuance of common shares of the Company pursuant to the exercise of options or warrants that were outstanding as of March 8, 2019 will be C$16.25 per common share without any set off, counterclaim, deduction, or withholding. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. The Altria Warrant, Pre-emptive Rights, and fixed price Top-up Rights have been classified as derivative liabilities. A reconciliation of the carrying amounts of the derivative liability for the three months ended June 30, 2021 and 2020: As of April 1, 2021 Revaluation gain Out-of-period adjustment Foreign exchange effect As of June 30, 2021 (a) Altria Warrant $ 234,656 $ (85,778) $ — $ 1,205 $ 150,083 (b) Pre-emptive Rights 20,173 (6,360) — 113 13,926 (c) Top-up Rights 17,471 (23,110) 11,278 (85) 5,554 $ 272,300 $ (115,248) $ 11,278 $ 1,233 $ 169,563 As of April 1, 2020 Revaluation loss Exercise of rights Foreign exchange effect As of June 30, 2020 (a) Altria Warrant $ 132,366 $ 30,052 $ — $ 3,540 $ 165,958 (b) Pre-emptive Rights 13,070 2,610 — 500 16,180 (c) Top-up Rights 20,013 3,218 (727) 1,072 23,576 $ 165,449 $ 35,880 $ (727) $ 5,112 $ 205,714 A reconciliation of the carrying amounts of the derivative liability for the six months ended June 30, 2021 and 2020: As of January 1, 2021 Revaluation loss/(gain) Exercise of rights Foreign exchange effect As of June 30, 2021 (a) Altria Warrant $ 138,858 $ 7,186 $ — $ 4,039 $ 150,083 (b) Pre-emptive Rights 12,095 1,473 — 358 13,926 (c) Top-up Rights 12,457 (7,033) — 130 5,554 $ 163,410 $ 1,626 $ — $ 4,527 $ 169,563 As of January 1, 2020 Revaluation loss/(gain) Exercise of rights Foreign exchange effect As of June 30, 2020 (a) Altria Warrant $ 234,428 $ (58,052) $ — $ (10,418) $ 165,958 (b) Pre-emptive Rights 12,787 3,925 — (532) 16,180 (c) Top-up Rights 49,945 (23,361) (727) (2,281) 23,576 $ 297,160 $ (77,488) $ (727) $ (13,231) $ 205,714 Fluctuations in the Company’s share price are a primary driver for the changes in the derivative valuations during each reporting period. As the share price decreases for each of the related derivative instruments, the liability of the instrument generally decreases. Share price is one of the significant observable inputs used in the fair value measurement of each of the Company’s derivative instruments. During the three months ended June 30, 2021, the Company’s share price decreased from April 1, 2021 and we recorded an out-of-period adjustment of $11,278. See Note 1. Background, Basis of Presentation and Accounting Policies for more information on the out-of-period adjustment. The fair values of the derivative liabilities were determined using the Black-Scholes pricing model as of June 30, 2021 and December 31, 2020 applying the following inputs: As of June 30, 2021 As of December 31, 2020 Altria Warrant Pre-emptive Rights Top-up Rights Altria Warrant Pre-emptive Rights Top-up Rights Share price at valuation date (i) $10.68 $10.68 $10.68 $8.84 $8.84 $8.84 Subscription price (i) $19.00 $16.25 $16.25 $19.00 $16.25 $16.25 Weighted average risk-free interest rate (ii) 0.38% 0.28% 0.31% 0.21% 0.17% 0.13% Weighted average expected life (iii) 1.68 1.25 1.31 2.18 1.50 0.98 Expected annualized volatility (iv) 75% 75% 75% 81% 81% 81% Expected dividend yield —% —% —% —% —% —% (i) Per share in C$. (ii) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of June 30, 2021 and December 31, 2020, the risk-free interest rate uses a range of approximately 0.15% to 0.85% and 0.10% to 0.39%, respectively, for the Pre-emptive Rights and Top-up Rights. (iii) The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of June 30, 2021 and December 31, 2020, the expected life uses a range of approximately 0.25 year to 4.25 years and 0.50 year to 5.00 years, respectively. (iv) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company as of June 30, 2021. As of December 31, 2020, volatility was based on the blended historical volatility levels of the Company and peer companies. The following table quantifies each of the significant inputs described above and provides a sensitivity analysis of the impact on the reported values of the derivative liabilities. The sensitivity analysis for each significant input is performed by assuming a 10% decrease in the input while other significant inputs remain constant at management’s best estimate as of the respective dates. While a decrease in the inputs noted below would cause a decrease in the carrying value of the derivative liability, there would also be an equal but opposite impact on net income (loss). Decrease as of June 30, 2021 Decrease as of December 31, 2020 Altria Warrant Pre-emptive Rights Top-up Rights Altria Warrant Pre-emptive Rights Top-up Rights Share price $ 31,375 $ 3,146 $ 1,302 $ 25,819 $ 2,527 $ 2,989 Weighted average expected life 14,220 5,266 502 13,541 1,988 2,121 Expected annualized volatility 27,375 2,348 968 26,183 2,269 2,602 These inputs are classified in Level 3 on the fair value hierarchy and are subject to volatility and several factors outside of the Company’s control, which could significantly affect the fair value of these derivative liabilities in future periods.

Share-based Payments

Share-based Payments	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Share-based Payments	Share-based Payments (a) Share-based award plans The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the Stock Option Plan dated May 26, 2015 (the “2015 Stock Option Plan”), the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan” and, together with the 2015 Stock Option Plan, the “Prior Option Plans”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the Prior Option Plans. The following table summarizes the total share-based payments associated with the Company’s stock options and RSUs for the three and six months ended June 30, 2021 and 2020: For the three months ended June 30, For the six months ended June 30, 2021 2020 2021 2020 Stock options $ 1,864 $ 1,770 $ 3,928 $ 3,500 RSUs 701 776 1,136 1,482 Total share-based payments $ 2,565 $ 2,546 $ 5,064 $ 4,982 (b) Stock options Vesting conditions for grants of options are determined by the Compensation Committee of the Company’s Board of Directors. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three three The following is a summary of the changes in stock options during the six months ended June 30, 2021 and 2020: Weighted average exercise price (C$) (i) Number of options Weighted average remaining contractual term (years) Balance as of January 1, 2021 $ 5.40 13,755,148 2.30 Exercise of options 2.14 (5,349,818) Cancellation, forfeiture and expiry of options 14.86 (33,699) Balance as of June 30, 2021 $ 7.45 8,371,631 2.66 Exercisable as of June 30, 2021 $ 6.49 4,679,240 1.43 (i) The weighted average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. Weighted average exercise price (C$) Number of options Weighted average remaining contractual term (years) Balance as of January 1, 2020 $ 4.84 14,149,502 2.56 Exercise of options 2.05 (1,807,909) Cancellation, forfeiture and expiry of options 15.78 (127,045) Balance as of June 30, 2020 $ 5.13 12,214,548 2.05 Exercisable as of June 30, 2020 $ 3.42 8,688,645 1.78 No stock options were granted during the six months ended June 30, 2021 and 2020. The following table summarizes stock options outstanding for the 2020 Omnibus Plan, the 2018 Stock Option Plan, and the 2015 Stock Option Plan: Stock options outstanding as of June 30, 2021 December 31, 2020 2020 Omnibus Plan 2,000,000 2,000,000 2018 Stock Option Plan 1,586,725 1,627,715 2015 Stock Option Plan 4,784,906 10,127,433 Total stock options outstanding 8,371,631 13,755,148 (c) Restricted share units The following is a summary of the changes in RSUs for the six months ended June 30, 2021 and 2020: Number of RSUs (i) Weighted average grant date fair value (C$) (ii) Balance as of January 1, 2021 948,357 $ 7.66 Granted (i) 515,433 11.29 Vested and issued (89,912) 7.52 Balance as of June 30, 2021 1,373,878 $ 9.03 Number of RSUs (i) Weighted average grant date fair value (C$) (ii) Balance as of January 1, 2020 732,972 $ 15.34 Granted (i) 279,277 7.52 Balance as of June 30, 2020 1,012,249 $ 13.18 (i) RSUs granted in the period vest annually in equal installments over a three-year period following the grant date, subject to such holder’s continued employment through each vesting date. The vesting of such RSUs is not subject to the achievement of any performance criteria. (ii) The weighted average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance. (d) Deferred share units The following is a summary of the changes in DSUs during the six months ended June 30, 2021 and 2020: Number of DSUs Financial liability Balance as of January 1, 2021 83,293 $ 577 Loss on revaluation — 141 Balance as of June 30, 2021 83,293 $ 718 Number of DSUs Financial liability Balance as of January 1, 2020 33,397 $ 255 DSU liabilities settled (8,484) (46) Gain on revaluation — (56) Balance as of June 30, 2020 24,913 $ 153 (e) Warrants The following is a summary of the changes in warrants during the six months ended June 30, 2021 and 2020: Weighted average exercise price (C$) Number of warrants Balance as of January 1, 2021 $ 0.25 7,987,349 Exercise of warrants 0.25 (7,987,349) Balance as of June 30, 2021 $ — — Weighted average exercise price (C$) Number of warrants Balance as of January 1, 2020 and June 30, 2020 $ 0.26 18,066,662 As of June 30, 2021, there are no warrants outstanding other than the Altria Warrant. See Note 5. Derivative Liabilities for further description on the Altria Warrant.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Earnings (Loss) per Share Basic and diluted earnings (loss) per share from continuing operations are calculated using the following numerators and denominators: For the three months ended June 30, For the six months ended June 30, 2021 2020 2021 2020 Basic earnings (loss) per share computation Net income (loss) from continuing operations attributable to the shareholders of Cronos Group $ 57,615 $ (106,931) $ (103,676) $ (30,891) Weighted average number of common shares outstanding 371,721,382 349,075,408 367,391,118 348,946,439 Basic earnings (loss) from continuing operations per share (i) $ 0.15 $ (0.31) $ (0.28) $ (0.09) Loss from discontinued operations attributable to the shareholders of Cronos Group $ (561) $ (46) $ (582) $ (46) Weighted average number of common shares outstanding 371,721,382 349,075,408 367,391,118 348,946,439 Basic earnings from discontinued operations per share $ 0.00 $ 0.00 $ 0.00 $ 0.00 Diluted earnings (loss) per share computation Net income (loss) used in the computation of basic earnings (loss) from continuing operations per share $ 57,615 $ (106,931) $ (103,676) $ (30,891) Adjustment for gain (loss) on revaluation of derivative liabilities — (729) — (729) Net income (loss) used in the computation of diluted earnings (loss) from continuing operations per share $ 57,615 $ (107,660) $ (103,676) $ (31,620) Weighted average number of common shares outstanding used in the computation of basic earnings (loss) per share 371,721,382 349,075,408 367,391,118 348,946,439 Dilutive effect of warrants 5,577 — — — Dilutive effect of stock options 3,027,518 — — — Dilutive effect of RSUs 595,379 — — — Weighted average number of common shares for computation of diluted earnings (loss) from continuing operations per share (i) 375,349,856 349,075,408 367,391,118 348,946,439 Diluted earnings (loss) from continuing operations per share $ 0.15 $ (0.31) $ (0.28) $ (0.09) Loss from discontinued operations attributable to the shareholders of Cronos Group $ (561) $ (46) $ (582) $ (46) Weighted average number of common shares for computation of diluted loss from discontinued operations per share 375,349,856 349,075,408 367,391,118 348,946,439 Diluted earnings from discontinued operations per share $ 0.00 $ 0.00 $ 0.00 $ 0.00 (i) In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive. The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive or because conditions for contingently issuable shares were not satisfied at the end of the reporting periods. Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Ginkgo equity milestones 14,674,904 14,674,904 14,674,904 14,674,904 Pre-emptive Rights 10,683,330 12,006,740 10,984,166 12,006,740 Top-up Rights – fixed price 3,698,611 26,686,413 7,406,031 26,686,413 Top-up Rights – market price 3,504,561 1,941,349 3,063,822 1,941,349 Altria Warrant 82,623,455 77,752,533 82,606,904 77,752,533 Stock options 1,411,944 10,495,235 6,136,113 10,547,256 Warrants — 17,521,903 2,784,377 17,536,558 Restricted share units 265,904 1,012,249 717,127 1,012,249 Total anti-dilutive securities 116,862,709 162,091,326 128,373,444 162,158,002

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Segment Information	Segment Information Segment reporting is prepared on the same basis that the Company’s chief operating decision makers (the “CODMs”) manage the business, make operating decisions and assess the Company’s performance. The Company determined that it has the following two reportable segments: United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets . These two segments represent the geographic regions in which the Company operates and the different product offerings within each geographic region. The results of each segment are regularly reviewed by the CODMs to assess the performance of the segment and make decisions regarding the allocation of resources. The CODMs review adjusted earnings (loss) before interest, tax, depreciation and amortization (“Adjusted EBITDA”) as the measure of segment profit or loss to evaluate performance of and allocate resources for its reportable segments. Adjusted EBITDA is defined as earnings before interest, tax, depreciation, non-cash items and items that do not reflect management’s assessment of on-going business performance. The tables below set forth our condensed consolidated results of operations, expressed in thousands of U.S. dollars for the periods presented. Our condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that we will achieve in future periods . Segment data was as follows for the three and six months ended June 30, 2021 and 2020: Three months ended June 30, 2021 United States Rest of World Corporate Expenses Total Cannabis flower $ — $ 11,597 $ — $ 11,597 Cannabis extracts 2,227 1,531 — 3,758 Other — 267 — 267 Net revenue $ 2,227 $ 13,395 $ — $ 15,622 Share of loss from equity accounted investments $ — $ 1,115 $ — $ 1,115 Interest income $ 20 $ 2,280 $ — $ 2,300 Interest expense — (7) — (7) Interest income, net $ 20 $ 2,273 $ — $ 2,293 Total assets $ 709,956 $ 386,805 $ 741,850 $ 1,838,611 Depreciation and amortization 68 975 — 1,043 Adjusted EBITDA (10,711) (32,605) (6,443) (49,759) Purchase of property, plant and equipment, net 239 1,428 — 1,667 Three months ended June 30, 2020 United States Rest of World Corporate Expenses Total Cannabis flower $ — $ 5,674 $ — $ 5,674 Cannabis extracts 2,174 1,917 — 4,091 Other — 118 — 118 Net revenue $ 2,174 $ 7,709 $ — $ 9,883 Share of loss from equity accounted investments $ — $ 794 $ — $ 794 Interest income 9 3,808 — 3,817 Interest expense — (83) — (83) Interest income, net $ 9 $ 3,725 $ — $ 3,734 Total assets $ 250,470 $ 348,569 $ 1,311,248 $ 1,910,287 Depreciation and amortization 36 643 — 679 Impairment loss on long-lived assets 40,000 — — 40,000 Adjusted EBITDA (4,785) (18,618) (3,583) (26,986) Purchase of property, plant and equipment, net 39 6,894 — 6,933 Six months ended June 30, 2021 United States Rest of World Corporate Expenses Total Cannabis flower $ — $ 21,031 $ — $ 21,031 Cannabis extracts 4,668 2,234 — 6,902 Other — 300 — 300 Net revenue $ 4,668 $ 23,565 $ — $ 28,233 Share of loss from equity accounted investments $ — $ 2,758 $ — $ 2,758 Interest income $ 23 $ 4,612 $ — $ 4,635 Interest expense — (13) — (13) Interest income, net $ 23 $ 4,599 $ — $ 4,622 Total assets $ 709,956 $ 386,805 $ 741,850 $ 1,838,611 Depreciation and amortization $ 139 $ 1,639 $ — $ 1,778 Impairment loss on long-lived assets 1,741 — — 1,741 Adjusted EBITDA (20,221) (54,789) (11,323) (86,333) Purchase of property, plant and equipment, net 319 8,028 — 8,347 Six months ended June 30, 2020 United States Rest of World Corporate Expenses Total Cannabis flower $ — $ 8,415 $ — $ 8,415 Cannabis extracts 4,350 5,317 — 9,667 Other — 233 — 233 Net revenue $ 4,350 $ 13,965 $ — $ 18,315 Share of loss from equity accounted investments $ — $ 1,966 $ — $ 1,966 Interest income 16 11,559 — 11,575 Interest expense — (90) — (90) Interest income, net $ 16 $ 11,469 $ — $ 11,485 Total assets $ 250,470 $ 348,569 $ 1,311,248 $ 1,910,287 Depreciation and amortization 69 1,297 — 1,366 Impairment loss on long-lived assets 40,000 — — 40,000 Adjusted EBITDA (10,567) (47,628) (5,846) (64,041) Purchase of property, plant and equipment, net 219 13,125 — 13,344 The following tables set forth a reconciliation of net income (loss) as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated: Three months ended June 30, 2021 United States Rest of World Corporate Expenses Total Net income (loss) $ (11,719) $ 79,627 $ (11,133) $ 56,775 Interest income, net (20) (2,273) — (2,293) Share of loss from equity accounted investments — 1,115 — 1,115 Gain on revaluation of derivative liabilities (ii) — (115,248) — (115,248) Transaction costs (iii) — — 2,758 2,758 Other, net (iv) — (1,127) — (1,127) Loss from discontinued operations (v) — 561 — 561 Share-based payments (vi) 822 1,743 — 2,565 Review costs related to restatement of 2019 interim financial statements (vii) — — 1,932 1,932 Depreciation and amortization 206 2,997 — 3,203 Adjusted EBITDA $ (10,711) $ (32,605) $ (6,443) $ (49,759) Three months ended June 30, 2020 United States Rest of World Corporate Total Net loss $ (45,566) $ (55,095) $ (7,042) $ (107,703) Interest income, net (9) (3,725) — (3,734) Share of loss from equity accounted investments — 794 — 794 Impairment loss on long-lived assets (i) 40,000 — — 40,000 Loss on revaluation of derivative liabilities (ii) — 35,880 — 35,880 Other, net (iv) — 9 — 9 Loss from discontinued operations (v) — 46 — 46 Share-based payments (vi) 756 1,790 — 2,546 Review costs related to restatement of 2019 interim financial statements (vii) — — 3,459 3,459 Depreciation and amortization 34 1,683 — 1,717 Adjusted EBITDA $ (4,785) $ (18,618) $ (3,583) $ (26,986) Six months ended June 30, 2021 United States Rest of World Corporate Expenses Total Net loss $ (23,811) $ (62,520) $ (18,519) $ (104,850) Interest income, net (23) (4,599) — (4,622) Share of loss from equity accounted investments — 2,758 — 2,758 Impairment loss on long-lived assets (i) 1,741 — — 1,741 Loss on revaluation of derivative liabilities (ii) — 1,626 — 1,626 Transaction costs (iii) — — 3,259 3,259 Other, net (iv) — (911) — (911) Loss from discontinued operations (v) — 582 — 582 Share-based payments (vi) 1,567 3,497 — 5,064 Review costs related to restatement of 2019 interim financial statements (vii) — — 3,937 3,937 Depreciation and amortization 305 4,778 — 5,083 Adjusted EBITDA $ (20,221) $ (54,789) $ (11,323) $ (86,333) Six months ended June 30, 2020 United States Rest of World Corporate Expenses Total Net income (loss) $ (52,082) $ 33,772 $ (13,712) $ (32,022) Interest income, net (16) (11,469) — (11,485) Share of loss from equity accounted investments — 1,966 — 1,966 Impairment loss on long-lived assets (i) 40,000 — — 40,000 Loss on revaluation of derivative liabilities (ii) — (77,488) — (77,488) Other, net (iv) — (785) — (785) Loss from discontinued operations (v) — 46 — 46 Share-based payments (vi) 1,462 3,520 — 4,982 Review costs related to restatement of 2019 interim financial statements (vii) — — 7,866 7,866 Depreciation and amortization 69 2,810 — 2,879 Adjusted EBITDA $ (10,567) $ (47,628) $ (5,846) $ (64,041) (i) For the six months ended June 30, 2021, impairment loss on long-lived assets relates to impairment on a leased premise in the U.S. segment, and for the three and six months ended June 30, 2020, impairment loss on long-lived assets relates to impairment on goodwill and intangibles related to our U.S. segment in 2020. See Note 12. Impairment Loss on Long-Lived Assets. (ii) For the three and six months ended June 30, 2021 and 2020, gain/loss on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. See Note 5. Derivative Liabilities. (iii) For the three and six months ended June 30, 2021, transaction costs represents legal, financial and other advisory fees and expenses incurred in connection with various strategic investments. These costs are included in general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss). (iv) For the three and six months ended June 30, 2021, other, net is related to gain recorded on sale of the Company’s Winnipeg facility previously designated as held-for-sale in the first quarter of 2021, For the three and six months ended June 30, 2020, other, net is primarily comprised of the gain recorded related to the sale of common shares of Aurora Cannabis, Inc. (“Aurora”), which were received in connection with the achievement of a milestone related to Aurora’s acquisition of Whistler Medical Marijuana Corporation. (v) For the three and six months ended June 30, 2020, loss from discontinued operations relates to the discontinuance of Original B.C. Ltd. (“OGBC”). See Note 11. Held-For-Sale Assets and Discontinued Operations. (vi) For the three and six months ended June 30, 2021 and 2020, share-based payments relates to the vesting expenses of share-based compensation awarded to employees under the Company’s share-based award plans as described in Note 6. Share-based Payments. (vii) For the three and six months ended June 30, 2021 and 2020, the financial statement review costs include costs related to the restatement of the Company’s 2019 interim financial statements, costs related to the Company’s responses to requests for information from various regulatory authorities relating to such restatement and legal costs defending shareholder class action complaints brought against the Company as a result of the restatement. Net revenue attributed to a geographic region based on the location of the customer were as follows: Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Canada $ 10,664 $ 7,416 $ 18,246 $ 13,507 Israel 2,310 293 4,828 293 United States 2,227 2,174 4,668 4,350 Other countries 421 — 491 165 Net revenue $ 15,622 $ 9,883 $ 28,233 $ 18,315 Property, plant and equipment assets were physically located in the following geographic regions: As of June 30, 2021 As of December 31, 2020 Canada $ 168,462 $ 162,163 Israel 23,936 23,143 United States 1,522 2,293 Total $ 193,920 $ 187,599 The Company sells products through a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenues. United States During the three and six months ended June 30, 2021 and 2020, the U.S. segment had no major customers. As of June 30, 2021 and December 31, 2020, the Company had $106 and $65, respectively, in expected credit losses that have been recognized on receivables from contracts with customers. There was no loss from discontinued operations from the U.S. Segment for the three and six months ended June 30, 2021 and 2020. Rest of World During the three months ended June 30, 2021, the Rest of World segment earned a total net revenue before excise taxes of $8,497 from three major customers, Ontario Cannabis Retail Corporation, Alberta Gaming, Liquor and Cannabis Commission and Société Québécoise du Cannabis, accounting for 19%, 14% and 12%, respectively, of the Company’s total net revenue before excise taxes. During the three months ended June 30, 2020, the Rest of World segment earned a total net revenue before excise taxes of $7,040 from four major customers, together accounting for 71% of the Company’s total net revenues before excise taxes. During the six months ended June 30, 2021, the Rest of World segment earned a total net revenue before excise taxes of $18,250 from four major customers, Ontario Cannabis Retail Corporation, Novolog Group, Société Québécoise du Cannabis and Alberta Gaming, Liquor and Cannabis Commission, accounting for 15%, 14%, 13%, and 12% respectively, of the Company’s total net revenue before excise taxes. During the six months ended June 30, 2020, the Rest of World segment earned a total net revenue before excise taxes of $11,819 from four major customers, together accounting for 65% of the Company’s total net revenues before excise taxes. As of June 30, 2021 and December 31, 2020, the Company had $158 and $9, respectively, in expected credit losses that have been recognized on receivables from contracts with customers. The loss from discontinued operations from the Rest of World segment for the three months ended June 30, 2021 and 2020 was $561 and $46, respectively. The loss from discontinued operations from the Rest of World segment for the six months ended June 30, 2021 and 2020 was $582 and $46, respectively.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Loss Contingency [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a) Commitments There have been no material changes in the information regarding commitments as disclosed in the Company’s Annual Financial Statements. (b) Contingencies The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its financial condition but could be material to its results of operations for a quarterly period depending, in part, on its results for that quarter. (i) Class action complaints relating to restatement On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its former Chief Executive Officer (now Executive Chairman) and Chief Financial Officer. The court has consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenues and internal controls were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board of Directors’ review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. Defendants moved to dismiss on February 8, 2021. On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim names the Company, its former Chief Executive Officer (now Executive Chairman), Chief Financial Officer, former Chief Financial Officer and Chief Commercial Officer, and current and former members of the Board of Directors as defendants and alleges breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleges that certain of the Company’s prior public statements about revenues and internal controls were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board of Directors was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim does not quantify a damage request. On June 28, 2021, the Ontario Court dismissed motions brought by the plaintiff for leave to commence a claim for misrepresentation under the Ontario Securities Act and for certification of the action as a class action. The plaintiff appealed the Court’s dismissal of the motions, except with respect to the former Chief Financial Officer and Chief Commercial Officer, who agreed not to seek costs from plaintiff in connection with the dismissal of the motions (ii) Regulatory reviews relating to restatement The Company has been responding to requests for information from various regulatory authorities relating to its previously disclosed restatement of its financial statements for the first three quarters of 2019. The Company is responding to all such requests for information and cooperating with all regulatory authorities. The Company cannot predict the outcome of any such regulatory review or investigation and it is possible that additional investigations or one or more formal proceedings may be commenced against the Company and its current and former officers and directors in connection with these regulatory reviews and investigations. (iii) Litigation relating to marketing, distribution and sale of products On June 16, 2020, an alleged consumer filed a Statement of Claim on behalf of a class in the Court of Queen’s Bench of Alberta in Alberta, Canada, against the Company and other Canadian cannabis manufacturers and/or distributors. On December 4, 2020, a Third Amended Statement of Claim was filed, which added a second alleged consumer. The Third Amended Statement of Claim alleges claims related to the defendants’ advertised content of cannabinoids in cannabis products for medicinal use on or after June 16, 2010 and cannabis products for adult use on or after October 17, 2018. The Third Amended Statement of Claim seeks a total of C$500 million for breach of contract, compensatory damages, and unjust enrichment or such other amount as may be proven in trial and C$5 million in punitive damages against each defendant, including the Company. The Third Amended Statement of Claim also seeks interest and costs associated with the action. The Company has not responded to the Third Amended Statement of Claim.

Financial Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2021
Risks and Uncertainties [Abstract]
Financial Instruments	Financial Instruments (a) Fair value measurement The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by: • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. • Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability. The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020 and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. June 30, 2021 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 895,181 $ — $ — $ 895,181 Short-term investments 201,699 — — 201,699 Derivative liabilities — — 169,563 169,563 December 31, 2020 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 1,078,023 $ — $ — $ 1,078,023 Short-term investments 211,766 — — 211,766 Derivative liabilities — — 163,410 163,410 There were no transfers between categories during the periods presented. (b) Financial risks The Company’s activities expose it to a variety of financial risks, including credit risk, market risk, interest rate risk, liquidity risk, and foreign currency rate risk. (i) Credit risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments, loans receivable, and advances to joint ventures. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $1,210,287 and $1,403,491 as of June 30, 2021 and December 31, 2020, respectively. (a) C ash and cash equivalents, short-term investments, and other receivables The Company held cash and cash equivalents and short-term investments and related interest receivable. Short-term investments and related interest receivable represents short-term investments with a maturity of less than a year and accrued interest as of period end. The cash and cash equivalents and short-term investments, including guaranteed investment certificates and bankers’ acceptances, are held with central banks and financial institutions that are highly rated. In addition to interest receivable, other receivables include sales taxes receivable from the government. As such, the Company has assessed an insignificant loss allowance on these financial instruments. (b) Accounts receivable An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, among others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of June 30, 2021 and December 31, 2020, the Company had an allowance for credit losses of $264 and $74, respectively. As of June 30, 2021, the Company has assessed that there is a concentration of credit risk, as 74% of the Company’s accounts receivable were due from four customers with an established credit history with the Company. As of December 31, 2020, 78% of the Company’s accounts receivable were due from four customers with an established credit history with the Company. (ii) Market risk Market risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in market prices. The value of financial instruments can be affected by changes in interest rates, market and economic conditions, and equity and commodity prices. The Company is exposed to market risk in divesting its investments, such that unfavorable market conditions could result in dispositions of investments at less than their carrying values. Further, the revaluation of securities classified as fair value through net income could result in significant write-downs of the Company’s investments, which would have an adverse impact on the Company’s financial position, unless these would flow through other comprehensive income. The Company manages market risk by having a portfolio of securities from multiple issuers so that the Company is not materially exposed to any one issuer. (iii) Interest rate risk Interest rate risk is the risk that the value or yield of fixed-income investments may decline if interest rates change. Fluctuations in interest rates may impact the level of income and expense recorded on the cash equivalents and short-term investments, and the market value of all interest-earning assets, other than those which possess a short-term to maturity. A 10% change in the interest rate in effect on June 30, 2021 and December 31, 2020 would not have a material effect on (i) fair value of the cash equivalents and short-term investments as the majority of the portfolio has a maturity date of three months or less or (ii) interest income. Management continues to monitor external interest rates and revise the Company’s investment strategy as a result. During the three months ended June 30, 2021 and 2020, the Company recorded net interest income of $2,293 and $3,734, respectively. During the six months ended June 30, 2021 and 2020, the Company recorded net interest income of $4,622 and $11,485, respectively. (iv) Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due and arises principally from the Company’s accounts payable and other liabilities. The Company’s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company’s management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise. The Company’s funding was primarily provided in the form of capital raised through the issuance of common shares and warrants. As of June 30, 2021, the Company had assessed a concentration risk of vendors as 32% of accounts payables were due to one vendor. As of December 31, 2020, the Company had assessed a concentration risk of vendors as 64% due to four vendors. (v) Foreign currency risk Currency rate risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in foreign exchange rates. The Company is exposed to this risk on investments in equity investees denominated in dollars, A$ and C$, and other assets and liabilities denominated in A$ and C$. The Company is further exposed to this risk through subsidiaries operating in Israel and the U.S. as the Company’s functional currency is in Canadian dollars. The Company does not currently use foreign exchange contracts to hedge its exposure to currency rate risk. As such, the Company’s financial position and financial results may be adversely affected by the unfavorable fluctuations in currency exchange rates. During the three months ended June 30, 2021 and 2020, the Company had foreign currency gain on translation of $13,470 and $51,871, respectively. During the six months ended June 30, 2021 and 2020, the Company had foreign currency gain (loss) on translation of $29,754 and $(61,821), respectively. A 10% change in the exchange rates for the U.S. dollar would affect the carrying value of net assets by approximately $162,991 and $170,817 as of June 30, 2021 and December 31, 2020, respectively.

Held-For-Sale Assets and Discon

Held-For-Sale Assets and Discontinued Operations	6 Months Ended
	Jun. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Held-For-Sale Assets and Discontinued Operations	Held-For-Sale Assets and Discontinued OperationsDuring the year ended December 31, 2020, the Company advanced its plans for the sale and disposal of substantially all of the assets of OGBC and as a result, OGBC’s results of operations were reclassified as discontinued operations in the accompanying condensed consolidated financial statements for all periods presented. During the quarter ended June 30, 2021, the Company determined that the fair value of OGBC was lower than the carrying value of the assets. As such, a write-down to these held-for-sale assets of $561 was recorded in the second quarter of 2021. As of June 30, 2021, the assets and liabilities of OGBC continue to meet the definition of discontinued operations and are included as “held-for-sale” assets on the condensed consolidated balance sheet as of June 30, 2021 and December 31, 2020, and loss from discontinued operations on the condensed consolidated statements of net income and comprehensive income for the three and six months ended June 30, 2021 and 2020. On June 10, 2021, the land and office building located in Winnipeg, Manitoba Canada, previously designated as held-for-sale in the first quarter of 2021, was sold for $2,059, net of costs to sell. As a result, the Company recorded a gain on the sale of $1,279 in other, net in its condensed consolidated income statement for the three and six months ended June 30, 2021. The following table summarizes the financial information for discontinued operations: Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Loss from discontinued operations, net of income taxes $ (561) $ (46) $ (582) $ (46) As of June 30, 2021 As of December 31, 2020 OGBC assets classified as held-for-sale $ 645 $ 1,176

Impairment Loss on Long-Lived A

Impairment Loss on Long-Lived Assets	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment Loss on Long-Lived Assets	Impairment Loss on Long-Lived Assets (a) Property, plant, and equipment, net and right-of-use assets During the six months ended June 30, 2021, the Company recognized an impairment charge of $1,039 related to leasehold improvements located within leased premises, encompassing approximately 6,000 square feet, in Los Angeles, California, which the Company determined it no longer had plans to use. The significant change in the extent and manner in which the leasehold improvements are being used and the expectation that, more likely than not, the leasehold improvements will be disposed of before the end of their useful life triggered an impairment. The right-of-use lease asset associated with the leasehold improvements was also written down as a result of our decision to no longer use the leased premises. The Company recognized an impairment charge on the de-recognition of the right-of-use asset of $702 during the six months ended June 30, 2021. Both of the impairment charges are recognized in the statement of net income (loss) as impairment loss on property, plant and equipment and right-of-use assets. No impairment charges were recorded during the three months ended June 30, 2021 and the three and six months ended June 30, 2020 on property, plant and equipment and right-of-use assets. (b) Intangible assets, net and goodwill Goodwill and indefinite life intangible assets are reviewed for impairment annually or more frequently when events or changes in circumstances indicate that fair value of the reporting unit has been reduced to less than its carrying value. During the three months ended June 30, 2020, the Company concluded that the projected impact of the COVID-19 pandemic on its sales and revenues in the near term, together with the volatility in the market conditions during the quarter, represented potential indicators of impairment for the Company’s U.S. reporting unit as well as its Lord Jones brand acquired in September 2019. Accordingly, the Company performed an interim impairment analysis during the second quarter of 2020. As a result of this analysis, the Company recorded impairment charges of $35,000 on its U.S. reporting unit and $5,000 on its Lord Jones™ brand for the three and six months ended June 30, 2020, when the carrying value of these assets exceeded their fair value. No triggering events were identified or impairment charges recorded during the three and six months ended June 30, 2021 on intangible assets and goodwill.

Background, Basis of Presenta_2

Background, Basis of Presentation and Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation The interim condensed consolidated financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2020 (the “Annual Financial Statements”). Certain prior year amounts have been reclassified to conform to the current year presentation of our condensed consolidated financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity.
Adoption of new accounting pronouncements and New accounting pronouncements not yet adopted	Adoption of new accounting pronouncements On January 1, 2021, the Company adopted ASU No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU No. 2020-01”). ASU No. 2020-01 clarifies the interaction of accounting for the transition into and out of the equity method as well as measuring certain purchased options and forward contracts to acquire investments. The adoption of ASU No. 2020-01 did not have an impact on the Company’s interim condensed consolidated financial statements. On January 1, 2021, the Company adopted ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU No. 2019-12”). ASU No. 2019-12 eliminates certain exceptions and simplifies the application of U.S. GAAP-related changes in enacted tax laws or rates and employee stock option plans. The adoption of ASU No. 2019-12 did not have an impact on the Company’s interim condensed consolidated financial statements. (e) New accounting pronouncements not yet adopted In August 2020, the FASB issued ASU 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815–40) (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU No. 2020-06 is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU No. 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU No. 2020-06 will have on its condensed consolidated financial statements.

Inventory, net (Tables)

Inventory, net (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net is comprised of the following items: As of June 30, 2021 As of December 31, 2020 Raw materials $ 7,471 $ 11,489 Work-in-progress 17,291 26,278 Finished goods 10,247 5,905 Supplies and consumables 596 330 Total $ 35,605 $ 44,002

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2021
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Investments in Associates and Joint Ventures	A reconciliation of the carrying amount of the investments in associates and joint ventures is as follows: Ownership interest As of June 30, 2021 As of December 31, 2020 Cronos Australia 31% $ — $ — Cronos GrowCo 50% 19,022 19,235 Natuera (i) 50% 1,948 — $ 20,970 $ 19,235 (i) On April 1, 2021, the Company and an affiliate of Agroidea (“AGI”), the other joint venture partner of Natuera, converted all advances made to Natuera under the master loan agreement entered into with Natuera on September 27, 2019 (the “Natuera Series A Loan”), plus accrued interest, into equity of Natuera. Total aggregate gross advances to Natuera under the Natuera Series A Loan were $15,500, of which the Company advanced 50% and AGI advanced the remaining 50%, or $7,750 each. As a result, the Company transferred the carrying value of the Natuera Series A Loan of approximately $2,013 plus accrued interest of $540, for a total investment value of $2,553, which approximates fair value, to investments in equity accounted investees in respect of Natuera. See Note 4. Loans Receivable, net. The Company’s share of net losses from equity investments accounted for under the equity method of accounting: For the three months ended June 30, For the six months ended June 30, 2021 2020 2021 2020 Cronos Australia $ — $ (235) $ — $ (235) Cronos GrowCo (459) (190) (758) (501) Natuera (656) (369) (2,000) (1,230) $ (1,115) $ (794) $ (2,758) $ (1,966)
Schedule of Variable Interest Entities	The following is a summary of the maximum exposure to loss as of June 30, 2021 and December 31, 2020: Ownership interest As of June 30, 2021 As of December 31, 2020 Cronos Australia 31% $ 1,573 $ 1,530 Cronos GrowCo 50% 21,723 21,125 MedMen Canada 50% 494 467 Natuera 50% 8,047 8,154 Total $ 31,837 $ 31,276

Loans Receivable, net (Tables)

Loans Receivable, net (Tables)	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Schedule of Loan Receivable	As of June 30, 2021 As of December 31, 2020 Natuera Series A Loan (i) $ — $ 3,518 GrowCo Facility (ii) 1,614 3,137 Add: Accrued interest 3,414 428 Total current portion of loans receivable 5,028 7,083 GrowCo Facility (ii) 77,474 69,939 Mucci Promissory Note (iii) 13,969 13,324 Cannasoul Collaboration Loan (iv) 1,870 1,261 Add: Accrued interest 800 2,667 Total long-term portion of loans receivable 94,113 87,191 Total loans receivable, net $ 99,141 $ 94,274 (i) On April 1, 2021, the Company and AGI converted all advances made to Natuera under the Series A Loan, plus accrued interest, into equity of Natuera. Total aggregate gross advances to Natuera under the Natuera Series A Loan were $15,500, of which the Company advanced 50% and AGI advanced the remaining 50%, or $7,750 each. As a result, the Company transferred the carrying value of the Natuera Series A Loan of approximately $2,013 plus accrued interest of $540, for a total investment value of $2,553, which approximates fair value, to investments in equity accounted investees in respect of Natuera. See Note 3. Investments. (ii) As of June 30, 2021 and December 31, 2020, Cronos GrowCo had drawn C$100,000 ($80,678) and C$95,150 ($74,626), respectively, from a credit agreement it entered into with the Company in August 2019 (the “GrowCo Facility”). As of June 30, 2021 and December 31, 2020, the Company had an allowance for credit losses of $1,590 and $1,470, respectively, recorded against the GrowCo Facility. (iii) As of June 30, 2021 and December 31, 2020, the Company had an allowance for credit losses of $278 and $259, respectively, recorded against the promissory note receivable agreement entered into with Mucci on June 28, 2019 (the “Mucci Promissory Note”). (iv) As of June 30, 2021 and December 31, 2020 CLS has received ILS 6,223 and ILS 4,149 (approximately $1,909 and $1,287 respectively) from the Cannasoul Collaboration Loan. As of June 30, 2021 and December 31, 2020, the Company had an allowance for credit losses of $39 and $25, respectively, recorded against the Cannasoul Collaboration Loan.

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Reconciliation of Carrying Amounts	A reconciliation of the carrying amounts of the derivative liability for the three months ended June 30, 2021 and 2020: As of April 1, 2021 Revaluation gain Out-of-period adjustment Foreign exchange effect As of June 30, 2021 (a) Altria Warrant $ 234,656 $ (85,778) $ — $ 1,205 $ 150,083 (b) Pre-emptive Rights 20,173 (6,360) — 113 13,926 (c) Top-up Rights 17,471 (23,110) 11,278 (85) 5,554 $ 272,300 $ (115,248) $ 11,278 $ 1,233 $ 169,563 As of April 1, 2020 Revaluation loss Exercise of rights Foreign exchange effect As of June 30, 2020 (a) Altria Warrant $ 132,366 $ 30,052 $ — $ 3,540 $ 165,958 (b) Pre-emptive Rights 13,070 2,610 — 500 16,180 (c) Top-up Rights 20,013 3,218 (727) 1,072 23,576 $ 165,449 $ 35,880 $ (727) $ 5,112 $ 205,714 A reconciliation of the carrying amounts of the derivative liability for the six months ended June 30, 2021 and 2020: As of January 1, 2021 Revaluation loss/(gain) Exercise of rights Foreign exchange effect As of June 30, 2021 (a) Altria Warrant $ 138,858 $ 7,186 $ — $ 4,039 $ 150,083 (b) Pre-emptive Rights 12,095 1,473 — 358 13,926 (c) Top-up Rights 12,457 (7,033) — 130 5,554 $ 163,410 $ 1,626 $ — $ 4,527 $ 169,563 As of January 1, 2020 Revaluation loss/(gain) Exercise of rights Foreign exchange effect As of June 30, 2020 (a) Altria Warrant $ 234,428 $ (58,052) $ — $ (10,418) $ 165,958 (b) Pre-emptive Rights 12,787 3,925 — (532) 16,180 (c) Top-up Rights 49,945 (23,361) (727) (2,281) 23,576 $ 297,160 $ (77,488) $ (727) $ (13,231) $ 205,714
Schedule of Fair Values of Derivative Liabilities	The fair values of the derivative liabilities were determined using the Black-Scholes pricing model as of June 30, 2021 and December 31, 2020 applying the following inputs: As of June 30, 2021 As of December 31, 2020 Altria Warrant Pre-emptive Rights Top-up Rights Altria Warrant Pre-emptive Rights Top-up Rights Share price at valuation date (i) $10.68 $10.68 $10.68 $8.84 $8.84 $8.84 Subscription price (i) $19.00 $16.25 $16.25 $19.00 $16.25 $16.25 Weighted average risk-free interest rate (ii) 0.38% 0.28% 0.31% 0.21% 0.17% 0.13% Weighted average expected life (iii) 1.68 1.25 1.31 2.18 1.50 0.98 Expected annualized volatility (iv) 75% 75% 75% 81% 81% 81% Expected dividend yield —% —% —% —% —% —% (i) Per share in C$. (ii) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of June 30, 2021 and December 31, 2020, the risk-free interest rate uses a range of approximately 0.15% to 0.85% and 0.10% to 0.39%, respectively, for the Pre-emptive Rights and Top-up Rights. (iii) The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of June 30, 2021 and December 31, 2020, the expected life uses a range of approximately 0.25 year to 4.25 years and 0.50 year to 5.00 years, respectively. (iv) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company as of June 30, 2021. As of December 31, 2020, volatility was based on the blended historical volatility levels of the Company and peer companies.
Schedule of Sensitivity Analysis	The following table quantifies each of the significant inputs described above and provides a sensitivity analysis of the impact on the reported values of the derivative liabilities. The sensitivity analysis for each significant input is performed by assuming a 10% decrease in the input while other significant inputs remain constant at management’s best estimate as of the respective dates. While a decrease in the inputs noted below would cause a decrease in the carrying value of the derivative liability, there would also be an equal but opposite impact on net income (loss). Decrease as of June 30, 2021 Decrease as of December 31, 2020 Altria Warrant Pre-emptive Rights Top-up Rights Altria Warrant Pre-emptive Rights Top-up Rights Share price $ 31,375 $ 3,146 $ 1,302 $ 25,819 $ 2,527 $ 2,989 Weighted average expected life 14,220 5,266 502 13,541 1,988 2,121 Expected annualized volatility 27,375 2,348 968 26,183 2,269 2,602

Share-based Payments (Tables)

Share-based Payments (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Summary of Stock-based Compensation Expense	The following table summarizes the total share-based payments associated with the Company’s stock options and RSUs for the three and six months ended June 30, 2021 and 2020: For the three months ended June 30, For the six months ended June 30, 2021 2020 2021 2020 Stock options $ 1,864 $ 1,770 $ 3,928 $ 3,500 RSUs 701 776 1,136 1,482 Total share-based payments $ 2,565 $ 2,546 $ 5,064 $ 4,982
Summary of the Changes in Options and Options Outstanding	The following is a summary of the changes in stock options during the six months ended June 30, 2021 and 2020: Weighted average exercise price (C$) (i) Number of options Weighted average remaining contractual term (years) Balance as of January 1, 2021 $ 5.40 13,755,148 2.30 Exercise of options 2.14 (5,349,818) Cancellation, forfeiture and expiry of options 14.86 (33,699) Balance as of June 30, 2021 $ 7.45 8,371,631 2.66 Exercisable as of June 30, 2021 $ 6.49 4,679,240 1.43 (i) The weighted average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. Weighted average exercise price (C$) Number of options Weighted average remaining contractual term (years) Balance as of January 1, 2020 $ 4.84 14,149,502 2.56 Exercise of options 2.05 (1,807,909) Cancellation, forfeiture and expiry of options 15.78 (127,045) Balance as of June 30, 2020 $ 5.13 12,214,548 2.05 Exercisable as of June 30, 2020 $ 3.42 8,688,645 1.78 The following table summarizes stock options outstanding for the 2020 Omnibus Plan, the 2018 Stock Option Plan, and the 2015 Stock Option Plan: Stock options outstanding as of June 30, 2021 December 31, 2020 2020 Omnibus Plan 2,000,000 2,000,000 2018 Stock Option Plan 1,586,725 1,627,715 2015 Stock Option Plan 4,784,906 10,127,433 Total stock options outstanding 8,371,631 13,755,148
Summary of Changes in RSUs	The following is a summary of the changes in RSUs for the six months ended June 30, 2021 and 2020: Number of RSUs (i) Weighted average grant date fair value (C$) (ii) Balance as of January 1, 2021 948,357 $ 7.66 Granted (i) 515,433 11.29 Vested and issued (89,912) 7.52 Balance as of June 30, 2021 1,373,878 $ 9.03 Number of RSUs (i) Weighted average grant date fair value (C$) (ii) Balance as of January 1, 2020 732,972 $ 15.34 Granted (i) 279,277 7.52 Balance as of June 30, 2020 1,012,249 $ 13.18 (i) RSUs granted in the period vest annually in equal installments over a three-year period following the grant date, subject to such holder’s continued employment through each vesting date. The vesting of such RSUs is not subject to the achievement of any performance criteria.
Summary of Changes in DSUs and Warrants	The following is a summary of the changes in DSUs during the six months ended June 30, 2021 and 2020: Number of DSUs Financial liability Balance as of January 1, 2021 83,293 $ 577 Loss on revaluation — 141 Balance as of June 30, 2021 83,293 $ 718 Number of DSUs Financial liability Balance as of January 1, 2020 33,397 $ 255 DSU liabilities settled (8,484) (46) Gain on revaluation — (56) Balance as of June 30, 2020 24,913 $ 153 The following is a summary of the changes in warrants during the six months ended June 30, 2021 and 2020: Weighted average exercise price (C$) Number of warrants Balance as of January 1, 2021 $ 0.25 7,987,349 Exercise of warrants 0.25 (7,987,349) Balance as of June 30, 2021 $ — — Weighted average exercise price (C$) Number of warrants Balance as of January 1, 2020 and June 30, 2020 $ 0.26 18,066,662

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share	Basic and diluted earnings (loss) per share from continuing operations are calculated using the following numerators and denominators: For the three months ended June 30, For the six months ended June 30, 2021 2020 2021 2020 Basic earnings (loss) per share computation Net income (loss) from continuing operations attributable to the shareholders of Cronos Group $ 57,615 $ (106,931) $ (103,676) $ (30,891) Weighted average number of common shares outstanding 371,721,382 349,075,408 367,391,118 348,946,439 Basic earnings (loss) from continuing operations per share (i) $ 0.15 $ (0.31) $ (0.28) $ (0.09) Loss from discontinued operations attributable to the shareholders of Cronos Group $ (561) $ (46) $ (582) $ (46) Weighted average number of common shares outstanding 371,721,382 349,075,408 367,391,118 348,946,439 Basic earnings from discontinued operations per share $ 0.00 $ 0.00 $ 0.00 $ 0.00 Diluted earnings (loss) per share computation Net income (loss) used in the computation of basic earnings (loss) from continuing operations per share $ 57,615 $ (106,931) $ (103,676) $ (30,891) Adjustment for gain (loss) on revaluation of derivative liabilities — (729) — (729) Net income (loss) used in the computation of diluted earnings (loss) from continuing operations per share $ 57,615 $ (107,660) $ (103,676) $ (31,620) Weighted average number of common shares outstanding used in the computation of basic earnings (loss) per share 371,721,382 349,075,408 367,391,118 348,946,439 Dilutive effect of warrants 5,577 — — — Dilutive effect of stock options 3,027,518 — — — Dilutive effect of RSUs 595,379 — — — Weighted average number of common shares for computation of diluted earnings (loss) from continuing operations per share (i) 375,349,856 349,075,408 367,391,118 348,946,439 Diluted earnings (loss) from continuing operations per share $ 0.15 $ (0.31) $ (0.28) $ (0.09) Loss from discontinued operations attributable to the shareholders of Cronos Group $ (561) $ (46) $ (582) $ (46) Weighted average number of common shares for computation of diluted loss from discontinued operations per share 375,349,856 349,075,408 367,391,118 348,946,439 Diluted earnings from discontinued operations per share $ 0.00 $ 0.00 $ 0.00 $ 0.00 (i) In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive.
Schedule of Antidilutive Securities Excluded from Computation of Diluted Shares Outstanding	The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive or because conditions for contingently issuable shares were not satisfied at the end of the reporting periods. Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Ginkgo equity milestones 14,674,904 14,674,904 14,674,904 14,674,904 Pre-emptive Rights 10,683,330 12,006,740 10,984,166 12,006,740 Top-up Rights – fixed price 3,698,611 26,686,413 7,406,031 26,686,413 Top-up Rights – market price 3,504,561 1,941,349 3,063,822 1,941,349 Altria Warrant 82,623,455 77,752,533 82,606,904 77,752,533 Stock options 1,411,944 10,495,235 6,136,113 10,547,256 Warrants — 17,521,903 2,784,377 17,536,558 Restricted share units 265,904 1,012,249 717,127 1,012,249 Total anti-dilutive securities 116,862,709 162,091,326 128,373,444 162,158,002

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Schedule of Segment Data and Adjusted EBITDA	Segment data was as follows for the three and six months ended June 30, 2021 and 2020: Three months ended June 30, 2021 United States Rest of World Corporate Expenses Total Cannabis flower $ — $ 11,597 $ — $ 11,597 Cannabis extracts 2,227 1,531 — 3,758 Other — 267 — 267 Net revenue $ 2,227 $ 13,395 $ — $ 15,622 Share of loss from equity accounted investments $ — $ 1,115 $ — $ 1,115 Interest income $ 20 $ 2,280 $ — $ 2,300 Interest expense — (7) — (7) Interest income, net $ 20 $ 2,273 $ — $ 2,293 Total assets $ 709,956 $ 386,805 $ 741,850 $ 1,838,611 Depreciation and amortization 68 975 — 1,043 Adjusted EBITDA (10,711) (32,605) (6,443) (49,759) Purchase of property, plant and equipment, net 239 1,428 — 1,667 Three months ended June 30, 2020 United States Rest of World Corporate Expenses Total Cannabis flower $ — $ 5,674 $ — $ 5,674 Cannabis extracts 2,174 1,917 — 4,091 Other — 118 — 118 Net revenue $ 2,174 $ 7,709 $ — $ 9,883 Share of loss from equity accounted investments $ — $ 794 $ — $ 794 Interest income 9 3,808 — 3,817 Interest expense — (83) — (83) Interest income, net $ 9 $ 3,725 $ — $ 3,734 Total assets $ 250,470 $ 348,569 $ 1,311,248 $ 1,910,287 Depreciation and amortization 36 643 — 679 Impairment loss on long-lived assets 40,000 — — 40,000 Adjusted EBITDA (4,785) (18,618) (3,583) (26,986) Purchase of property, plant and equipment, net 39 6,894 — 6,933 Six months ended June 30, 2021 United States Rest of World Corporate Expenses Total Cannabis flower $ — $ 21,031 $ — $ 21,031 Cannabis extracts 4,668 2,234 — 6,902 Other — 300 — 300 Net revenue $ 4,668 $ 23,565 $ — $ 28,233 Share of loss from equity accounted investments $ — $ 2,758 $ — $ 2,758 Interest income $ 23 $ 4,612 $ — $ 4,635 Interest expense — (13) — (13) Interest income, net $ 23 $ 4,599 $ — $ 4,622 Total assets $ 709,956 $ 386,805 $ 741,850 $ 1,838,611 Depreciation and amortization $ 139 $ 1,639 $ — $ 1,778 Impairment loss on long-lived assets 1,741 — — 1,741 Adjusted EBITDA (20,221) (54,789) (11,323) (86,333) Purchase of property, plant and equipment, net 319 8,028 — 8,347 Six months ended June 30, 2020 United States Rest of World Corporate Expenses Total Cannabis flower $ — $ 8,415 $ — $ 8,415 Cannabis extracts 4,350 5,317 — 9,667 Other — 233 — 233 Net revenue $ 4,350 $ 13,965 $ — $ 18,315 Share of loss from equity accounted investments $ — $ 1,966 $ — $ 1,966 Interest income 16 11,559 — 11,575 Interest expense — (90) — (90) Interest income, net $ 16 $ 11,469 $ — $ 11,485 Total assets $ 250,470 $ 348,569 $ 1,311,248 $ 1,910,287 Depreciation and amortization 69 1,297 — 1,366 Impairment loss on long-lived assets 40,000 — — 40,000 Adjusted EBITDA (10,567) (47,628) (5,846) (64,041) Purchase of property, plant and equipment, net 219 13,125 — 13,344 The following tables set forth a reconciliation of net income (loss) as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated: Three months ended June 30, 2021 United States Rest of World Corporate Expenses Total Net income (loss) $ (11,719) $ 79,627 $ (11,133) $ 56,775 Interest income, net (20) (2,273) — (2,293) Share of loss from equity accounted investments — 1,115 — 1,115 Gain on revaluation of derivative liabilities (ii) — (115,248) — (115,248) Transaction costs (iii) — — 2,758 2,758 Other, net (iv) — (1,127) — (1,127) Loss from discontinued operations (v) — 561 — 561 Share-based payments (vi) 822 1,743 — 2,565 Review costs related to restatement of 2019 interim financial statements (vii) — — 1,932 1,932 Depreciation and amortization 206 2,997 — 3,203 Adjusted EBITDA $ (10,711) $ (32,605) $ (6,443) $ (49,759) Three months ended June 30, 2020 United States Rest of World Corporate Total Net loss $ (45,566) $ (55,095) $ (7,042) $ (107,703) Interest income, net (9) (3,725) — (3,734) Share of loss from equity accounted investments — 794 — 794 Impairment loss on long-lived assets (i) 40,000 — — 40,000 Loss on revaluation of derivative liabilities (ii) — 35,880 — 35,880 Other, net (iv) — 9 — 9 Loss from discontinued operations (v) — 46 — 46 Share-based payments (vi) 756 1,790 — 2,546 Review costs related to restatement of 2019 interim financial statements (vii) — — 3,459 3,459 Depreciation and amortization 34 1,683 — 1,717 Adjusted EBITDA $ (4,785) $ (18,618) $ (3,583) $ (26,986) Six months ended June 30, 2021 United States Rest of World Corporate Expenses Total Net loss $ (23,811) $ (62,520) $ (18,519) $ (104,850) Interest income, net (23) (4,599) — (4,622) Share of loss from equity accounted investments — 2,758 — 2,758 Impairment loss on long-lived assets (i) 1,741 — — 1,741 Loss on revaluation of derivative liabilities (ii) — 1,626 — 1,626 Transaction costs (iii) — — 3,259 3,259 Other, net (iv) — (911) — (911) Loss from discontinued operations (v) — 582 — 582 Share-based payments (vi) 1,567 3,497 — 5,064 Review costs related to restatement of 2019 interim financial statements (vii) — — 3,937 3,937 Depreciation and amortization 305 4,778 — 5,083 Adjusted EBITDA $ (20,221) $ (54,789) $ (11,323) $ (86,333) Six months ended June 30, 2020 United States Rest of World Corporate Expenses Total Net income (loss) $ (52,082) $ 33,772 $ (13,712) $ (32,022) Interest income, net (16) (11,469) — (11,485) Share of loss from equity accounted investments — 1,966 — 1,966 Impairment loss on long-lived assets (i) 40,000 — — 40,000 Loss on revaluation of derivative liabilities (ii) — (77,488) — (77,488) Other, net (iv) — (785) — (785) Loss from discontinued operations (v) — 46 — 46 Share-based payments (vi) 1,462 3,520 — 4,982 Review costs related to restatement of 2019 interim financial statements (vii) — — 7,866 7,866 Depreciation and amortization 69 2,810 — 2,879 Adjusted EBITDA $ (10,567) $ (47,628) $ (5,846) $ (64,041) (i) For the six months ended June 30, 2021, impairment loss on long-lived assets relates to impairment on a leased premise in the U.S. segment, and for the three and six months ended June 30, 2020, impairment loss on long-lived assets relates to impairment on goodwill and intangibles related to our U.S. segment in 2020. See Note 12. Impairment Loss on Long-Lived Assets. (ii) For the three and six months ended June 30, 2021 and 2020, gain/loss on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. See Note 5. Derivative Liabilities. (iii) For the three and six months ended June 30, 2021, transaction costs represents legal, financial and other advisory fees and expenses incurred in connection with various strategic investments. These costs are included in general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss). (iv) For the three and six months ended June 30, 2021, other, net is related to gain recorded on sale of the Company’s Winnipeg facility previously designated as held-for-sale in the first quarter of 2021, For the three and six months ended June 30, 2020, other, net is primarily comprised of the gain recorded related to the sale of common shares of Aurora Cannabis, Inc. (“Aurora”), which were received in connection with the achievement of a milestone related to Aurora’s acquisition of Whistler Medical Marijuana Corporation. (v) For the three and six months ended June 30, 2020, loss from discontinued operations relates to the discontinuance of Original B.C. Ltd. (“OGBC”). See Note 11. Held-For-Sale Assets and Discontinued Operations. (vi) For the three and six months ended June 30, 2021 and 2020, share-based payments relates to the vesting expenses of share-based compensation awarded to employees under the Company’s share-based award plans as described in Note 6. Share-based Payments.
Schedule of Revenue from External Customers by Geographic Areas	Net revenue attributed to a geographic region based on the location of the customer were as follows: Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Canada $ 10,664 $ 7,416 $ 18,246 $ 13,507 Israel 2,310 293 4,828 293 United States 2,227 2,174 4,668 4,350 Other countries 421 — 491 165 Net revenue $ 15,622 $ 9,883 $ 28,233 $ 18,315
Schedule of Long-lived Assets by Geographic Areas	Property, plant and equipment assets were physically located in the following geographic regions: As of June 30, 2021 As of December 31, 2020 Canada $ 168,462 $ 162,163 Israel 23,936 23,143 United States 1,522 2,293 Total $ 193,920 $ 187,599

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2021
Risks and Uncertainties [Abstract]
Schedule of Fair Value of Assets Measured on Recurring Basis	The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2021 and December 31, 2020 and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. June 30, 2021 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 895,181 $ — $ — $ 895,181 Short-term investments 201,699 — — 201,699 Derivative liabilities — — 169,563 169,563 December 31, 2020 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 1,078,023 $ — $ — $ 1,078,023 Short-term investments 211,766 — — 211,766 Derivative liabilities — — 163,410 163,410

Held-For-Sale Assets and Disc_2

Held-For-Sale Assets and Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Summary of Financial Information for Discontinued Operations	The following table summarizes the financial information for discontinued operations: Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Loss from discontinued operations, net of income taxes $ (561) $ (46) $ (582) $ (46) As of June 30, 2021 As of December 31, 2020 OGBC assets classified as held-for-sale $ 645 $ 1,176

Background, Basis of Presenta_3

Background, Basis of Presentation and Accounting Policies (Details) $ in Thousands		3 Months Ended			6 Months Ended		12 Months Ended
		Jun. 30, 2021USD ($)continentbrand	Mar. 31, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)continentbrand	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Schedule of Equity Method Investments [Line Items]
Number of continents with international production and distribution | continent		5			5
Number of adult-use brands | brand		2			2
Number of hemp-derived cannabidiol personal care brands | brand		3			3
Accounts payable and other liabilities		$ 29,829			$ 29,829		$ 42,102
Other receivables		2,468			2,468		10,033
Retained earnings		955,721			955,721		1,064,509
Share capital	[1],[2]	572,858			572,858		569,260
Gain (loss) on revaluation of derivative liabilities		$ 115,248		$ (35,880)	$ (1,626)	$ 77,488
Error Correction, Adjustment | Error Related to Withholding Taxes on the Net Exercise of Stock Options
Schedule of Equity Method Investments [Line Items]
Accounts payable and other liabilities							966
Other receivables							(3,202)
Retained earnings							(3,838)
Share capital							(330)
Error Correction, Adjustment | Error Related to Exercise of Top-up Rights
Schedule of Equity Method Investments [Line Items]
Retained earnings			$ 3,227
Share capital			(14,505)				(3,227)
Gain (loss) on revaluation of derivative liabilities			$ 11,278				$ 3,227
Cronos Australia
Schedule of Equity Method Investments [Line Items]
Ownership interest		31.00%			31.00%
[1]	Authorized for issuance as of June 30, 2021: unlimited and December 31, 2020: unlimited.
[2]	Shares issued as of June 30, 2021: 371,805,547 and December 31, 2020: 360,253,332.

Inventory, net (Details)

Inventory, net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 7,471		$ 7,471		$ 11,489
Work-in-progress	17,291		17,291		26,278
Finished goods	10,247		10,247		5,905
Supplies and consumables	596		596		330
Inventory, net	35,605		35,605		$ 44,002
Inventory write-down	$ 11,961	$ 3,062	$ 11,961	$ 11,024

Investments - Narrative (Detail

Investments - Narrative (Details) $ / shares in Units, ₪ in Thousands, $ in Thousands	Jun. 14, 2021USD ($)$ / sharesshares	Jun. 14, 2018	Mar. 13, 2018	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021ILS (₪)
Variable Interest Entity [Line Items]
Sale of stock, price per share (in dollars per share) | $ / shares	$ 0.0001
Sale of stock, percentage of ownership after transaction	10.50%
Purchase of other investments | $	$ 110,392			$ 110,392	$ 0
Pharmacann
Variable Interest Entity [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	473,787
Cronos GrowCo | Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership percentage		50.00%		50.00%
MedMen Canada | Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership percentage			50.00%	50.00%
Natuera | Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership percentage				50.00%
Cannasoul | Establishment of a Commercial Cannabis Analytical Testing Laboratory | Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Collaboration agreement, percentage of profits to be received				70.00%		70.00%
Collaboration agreement, profits to be received, maximum percentage of amounts advanced				150.00%		150.00%
Collaboration agreement, percentage of profits to be received, triggering event, subsequent to maximum percentage of amounts advanced being met				50.00%		50.00%
Cannasoul | Establishment of a Commercial Cannabis Analytical Testing Laboratory | Variable Interest Entity, Not Primary Beneficiary | Cannasoul collaboration loan | Loans Receivable
Variable Interest Entity [Line Items]
Collaboration agreement, amount of advances				$ 2,511		₪ 8,297
Collaboration agreement, term of agreement				2 years
Interest rate				3.50%		3.50%
Minimum | MedMen Canada | Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
License term			20 years

Investments - Schedule of Inves

Investments - Schedule of Investments in Associates and Joint Ventures (Details) $ in Thousands	Apr. 01, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Schedule of Equity Method Investments [Line Items]
Investments in equity accounted investees, net		$ 20,970		$ 20,970		$ 19,235
Transfer to investments in equity accounted investees, excluding accrued interest		99,141		99,141		94,274
Share of loss from investments in equity accounted investees		$ (1,115)	$ (794)	$ (2,758)	$ (1,966)
NatuEra Series A Loan | Loans Receivable
Schedule of Equity Method Investments [Line Items]
Advances to affiliates	$ 15,500
Transfer to investments in equity accounted investees, excluding accrued interest	2,013
Accrued interest	540
Transfer to investments in equity accounted investees	2,553
NatuEra Series A Loan | Loans Receivable | Cronos Group, Inc.
Schedule of Equity Method Investments [Line Items]
Advances to affiliates	$ 7,750
Funding commitment percentage	0.50
NatuEra Series A Loan | Loans Receivable | AGI
Schedule of Equity Method Investments [Line Items]
Advances to affiliates	$ 7,750
Funding commitment percentage	0.50
Cronos Australia
Schedule of Equity Method Investments [Line Items]
Ownership interest		31.00%		31.00%
Investments in equity accounted investees, net		$ 0		$ 0		0
Share of loss from investments in equity accounted investees		$ 0	(235)	$ 0	(235)
Cronos GrowCo
Schedule of Equity Method Investments [Line Items]
Ownership interest		50.00%		50.00%
Investments in equity accounted investees, net		$ 19,022		$ 19,022		19,235
Share of loss from investments in equity accounted investees		$ (459)	(190)	$ (758)	(501)
Natuera
Schedule of Equity Method Investments [Line Items]
Ownership interest		50.00%		50.00%
Investments in equity accounted investees, net		$ 1,948		$ 1,948		$ 0
Share of loss from investments in equity accounted investees		$ (656)	$ (369)	$ (2,000)	$ (1,230)

Investments - Schedule of Varia

Investments - Schedule of Variable Interest Entities (Details) - USD ($) $ in Thousands	Jun. 14, 2018	Mar. 13, 2018	Jun. 30, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Maximum Exposure to Loss			$ 31,837	$ 31,276
Cronos Australia | Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership interest			31.00%
Maximum Exposure to Loss			$ 1,573	1,530
Cronos GrowCo | Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership interest	50.00%		50.00%
Maximum Exposure to Loss			$ 21,723	21,125
MedMen Canada | Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership interest		50.00%	50.00%
Maximum Exposure to Loss			$ 494	467
Natuera | Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership interest			50.00%
Maximum Exposure to Loss			$ 8,047	$ 8,154

Loans Receivable, net (Details)

Loans Receivable, net (Details) ₪ in Thousands, $ in Thousands, $ in Thousands	Apr. 01, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2021CAD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2019CAD ($)	Jun. 30, 2021ILS (₪)	Dec. 31, 2020USD ($)	Dec. 31, 2020ILS (₪)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total current portion of loans receivable		$ 5,028						$ 7,083
Total long-term portion of loans receivable		94,113						87,191
Total loans receivable, net		99,141						94,274
Draw downs		5,064		$ 23,974
Current expected credit loss allowance on accounts receivable		264						74
Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Add: Accrued interest		3,414						428
Add: Accrued interest		800						2,667
NatuEra Series A Loan | Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current portion of loans receivable, before accrued interest		0						3,518
Total loans receivable, net	$ 2,013
Advances to affiliates	15,500
Accrued interest	540
Transfer to investments in equity accounted investees	2,553
NatuEra Series A Loan | Loans Receivable | Cronos Group, Inc.
Accounts, Notes, Loans and Financing Receivable [Line Items]
Advances to affiliates	$ 7,750
Funding commitment percentage	0.50
NatuEra Series A Loan | Loans Receivable | AGI
Accounts, Notes, Loans and Financing Receivable [Line Items]
Advances to affiliates	$ 7,750
Funding commitment percentage	0.50
GrowCo Facility | Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current portion of loans receivable, before accrued interest		1,614						3,137
Long term portion of loans receivable, before accrued interest		77,474						69,939
Draw downs		80,678	$ 100,000		$ 74,626	$ 95,150
Allowance for credit loss		1,590						1,470
Mucci promissory note | Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest		13,969						13,324
Allowance for credit loss		278						259
Cannasoul collaboration loan | Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest		1,870						1,261
Cannasoul collaboration loan | Loans Receivable | Establishment of a Commercial Cannabis Analytical Testing Laboratory | Cannasoul | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collaborative arrangement, installment received		1,909					₪ 6,223	1,287	₪ 4,149
Current expected credit loss allowance on accounts receivable		$ 39						$ 25

Derivative Liabilities - Narrat

Derivative Liabilities - Narrative (Details) $ in Thousands	Mar. 08, 2019warrantday$ / sharesshares	Jun. 30, 2021USD ($)shares
Derivative [Line Items]
Derivative liability, out-of-period adjustment		$ 11,278
Altria Group, Inc. | Cronos Group, Inc.
Derivative [Line Items]
Ownership interest	45.00%	42.00%
Altria Investment
Derivative [Line Items]
Shares issued (in shares) | shares	149,831,154
Cronos Group, Inc. | Altria Group, Inc.
Derivative [Line Items]
Ownership percentage, if warrant exercised	55.00%	53.00%
Altria Investment
Derivative [Line Items]
Maximum additional subscription percentage	10.00%
Derivative liability, additional subscription (in shares) | shares		83,000,000
Altria Warrant
Derivative [Line Items]
Number of warrants issued | warrant	1
Exercise price (in dollars per share) | $ / shares	$ 19
Derivative liability, out-of-period adjustment		$ 0
Pre-emptive Rights
Derivative [Line Items]
Exercise price (in dollars per share) | $ / shares	$ 16.25
Exercise rights, minimum ownership percentage	20.00%
Derivative liability, out-of-period adjustment		0
Top-up Rights
Derivative [Line Items]
Exercise price (in dollars per share) | $ / shares	$ 16.25
Exercise rights, minimum ownership percentage	20.00%
Exercise price, volume-weighted average price, measurement period	10 days
Exercise price, volume-weighted average price, measurement period, days preceding exercise | day	10
Derivative liability, out-of-period adjustment		$ 11,278

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Reconciliation of Carrying Amounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Derivative Instruments [Roll Forward]
Beginning balance	$ 272,300	$ 165,449	$ 163,410	$ 297,160
Revaluation loss/(gain)	(115,248)	35,880	1,626	(77,488)
Exercise of rights		(727)	0	(727)
Out-of-period adjustment	11,278
Foreign exchange effect	1,233	5,112	4,527	(13,231)
Ending balance	169,563	205,714	169,563	205,714
Altria Warrant
Derivative Instruments [Roll Forward]
Beginning balance	234,656	132,366	138,858	234,428
Revaluation loss/(gain)	(85,778)	30,052	7,186	(58,052)
Exercise of rights		0	0	0
Out-of-period adjustment	0
Foreign exchange effect	1,205	3,540	4,039	(10,418)
Ending balance	150,083	165,958	150,083	165,958
Pre-emptive Rights
Derivative Instruments [Roll Forward]
Beginning balance	20,173	13,070	12,095	12,787
Revaluation loss/(gain)	(6,360)	2,610	1,473	3,925
Exercise of rights		0	0	0
Out-of-period adjustment	0
Foreign exchange effect	113	500	358	(532)
Ending balance	13,926	16,180	13,926	16,180
Top-up Rights
Derivative Instruments [Roll Forward]
Beginning balance	17,471	20,013	12,457	49,945
Revaluation loss/(gain)	(23,110)	3,218	(7,033)	(23,361)
Exercise of rights		(727)	0	(727)
Out-of-period adjustment	11,278
Foreign exchange effect	(85)	1,072	130	(2,281)
Ending balance	$ 5,554	$ 23,576	$ 5,554	$ 23,576

Derivative Liabilities - Sche_2

Derivative Liabilities - Schedule of Fair Values of Derivative Liabilities (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2021$ / shares	Dec. 31, 2020$ / shares
Altria Warrant | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	10.68	8.84
Altria Warrant | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	19	19
Altria Warrant | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.75	0.81
Altria Warrant | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Altria Warrant | Weighted Average | Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0038	0.0021
Altria Warrant | Weighted Average | Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	1 year 8 months 4 days	2 years 2 months 4 days
Pre-emptive Rights | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	10.68	8.84
Pre-emptive Rights | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Pre-emptive Rights | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.75	0.81
Pre-emptive Rights | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Pre-emptive Rights | Weighted Average | Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0028	0.0017
Pre-emptive Rights | Weighted Average | Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	1 year 3 months	1 year 6 months
Top-up Rights | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	10.68	8.84
Top-up Rights | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Top-up Rights | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.75	0.81
Top-up Rights | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Top-up Rights | Weighted Average | Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0031	0.0013
Top-up Rights | Weighted Average | Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	1 year 3 months 21 days	11 months 23 days
Pre-emptive Rights and Top-up Rights | Minimum | Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0015	0.0010
Pre-emptive Rights and Top-up Rights | Minimum | Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	3 months	6 months
Pre-emptive Rights and Top-up Rights | Maximum | Weighted average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0085	0.0039
Pre-emptive Rights and Top-up Rights | Maximum | Weight average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	4 years 3 months	5 years

Derivative Liabilities - Sche_3

Derivative Liabilities - Schedule of Sensitivity Analysis (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Altria Warrant
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	$ 31,375	$ 25,819
Weighted average expected life	14,220	13,541
Expected annualized volatility	27,375	26,183
Pre-emptive Rights
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	3,146	2,527
Weighted average expected life	5,266	1,988
Expected annualized volatility	2,348	2,269
Top-up Rights
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	1,302	2,989
Weighted average expected life	502	2,121
Expected annualized volatility	$ 968	$ 2,602

Share-based Payments - Summary

Share-based Payments - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	$ 2,565	$ 2,546	$ 5,064	$ 4,982
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	1,864	1,770	3,928	3,500
Restricted share units
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payments	$ 701	$ 776	$ 1,136	$ 1,482

Share-based Payments - Stock Op

Share-based Payments - Stock Options Narrative (Details) - shares	Mar. 29, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of options (in shares)		0	0
Stock options | 2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Stock options | Prior Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	7 years
Minimum | Stock options | 2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Minimum | Stock options | Prior Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum | Stock options | 2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
Maximum | Stock options | Prior Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Share-based Payments - Summar_2

Share-based Payments - Summary of the Changes in Options (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2021$ / shares$ / sharesshares	Jun. 30, 2020$ / shares$ / sharesshares	Dec. 31, 2020$ / sharesshares	Dec. 31, 2019$ / sharesshares
Weighted average exercise price (C$)
Balance at beginning of period (in dollars per share) | $ / shares	$ 5.40	$ 4.84	$ 4.84
Exercise of options (in dollars per share) | $ / shares	2.14	2.05
Cancellation, forfeiture and expiry of options (in dollars per share) | $ / shares	14.86	15.78
Balance at end of period (in dollars per share) | $ / shares	$ 7.45	$ 5.13	$ 5.40	$ 4.84
Weighted average exercise price of options exercisable (in dollars per share) | $ / shares	$ 6.49	$ 3.42
Number of options
Balance at beginning of period (in shares) | shares	13,755,148	14,149,502	14,149,502
Exercise of options (in shares) | shares	(5,349,818)	(1,807,909)
Cancellation, forfeiture and expiry of options (in shares) | shares	(33,699)	(127,045)
Balance at end of period (in shares) | shares	8,371,631	12,214,548	13,755,148	14,149,502
Exercisable (in shares) | shares	4,679,240	8,688,645
Weighted average remaining contractual term (years)
Outstanding	2 years 7 months 28 days	2 years 18 days	2 years 3 months 18 days	2 years 6 months 21 days
Exercisable	1 year 5 months 4 days	1 year 9 months 10 days

Share-based Payments - Schedule

Share-based Payments - Schedule of Stock Options Outstanding (Details) - shares	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	8,371,631	13,755,148	12,214,548	14,149,502
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	2,000,000	2,000,000
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	1,586,725	1,627,715
2015 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	4,784,906	10,127,433

Share-based Payments - Summar_3

Share-based Payments - Summary of Changes in RSUs (Details) - Restricted share units - $ / shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Number of awards
Balance at beginning of period (in shares)	948,357	732,972
Granted (in shares)	515,433	279,277
Vested and issued/liabilities settled (in shares)	(89,912)
Balance at end of period (in shares)	1,373,878	1,012,249
Deferred Compensation Share-based Arrangements, Liability [Roll Forward]
Balance at beginning of period (in dollars per share)	$ 7.66	$ 15.34
Granted (in dollars per share)	11.29	7.52
Vested and issued (in dollars per share)	7.52
Balance at end of period (in dollars per share)	$ 9.03	$ 13.18
Vesting period	3 years	3 years

Share-based Payments - Summar_4

Share-based Payments - Summary of DSU Activity (Details) - Deferred Share Units (DSUs) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Number of awards
Balance at beginning of period (in shares)	83,293	33,397
Vested and issued/liabilities settled (in shares)		(8,484)
Balance at end of period (in shares)	83,293	24,913
Financial liability
Balance at beginning of period	$ 577	$ 255
DSU liabilities settled		(46)
Loss on revaluation	141	(56)
Balance at end of period	$ 718	$ 153

Share-based Payments - Summar_5

Share-based Payments - Summary of Changes in Warrants (Details) - Warrants - $ / shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Weighted average exercise price (C$)
Balance at beginning of period (in dollars per share)	$ 0.25	$ 0.26
Exercise of warrants (in dollars per share)	0.25
Balance at end of period (in dollars per share)	$ 0	$ 0.26
Number of awards
Balance at beginning of period (in shares)	7,987,349	18,066,662
Exercise of warrants (in shares)	(7,987,349)
Balance at end of period (in shares)	0	18,066,662

Share-based Payments - Summar_6

Share-based Payments - Summary of Outstanding Warrants (Details) - shares	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants (in shares)	0	7,987,349	18,066,662	18,066,662

Earnings (Loss) Per Share - Sch

Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Basic earnings (loss) per share computation
Net income (loss) from continuing operations attributable to the shareholders of Cronos Group	$ 57,615	$ (106,931)	$ (103,676)	$ (30,891)
Weighted average number of common shares outstanding (in shares)	371,721,382	349,075,408	367,391,118	348,946,439
Basic earnings (loss) from continuing operations per share (in dollars per share)	$ 0.15	$ (0.31)	$ (0.28)	$ (0.09)
Loss from discontinued operations attributable to the shareholders of Cronos Group	$ (561)	$ (46)	$ (582)	$ (46)
Basic earnings from discontinued operations per share (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Diluted earnings (loss) per share computation
Net income (loss) used in the computation of basic earnings (loss) from continuing operations per share	$ 57,615	$ (106,931)	$ (103,676)	$ (30,891)
Adjustment for gain (loss) on revaluation of derivative liabilities	0	(729)	0	(729)
Net income (loss) used in the computation of diluted earnings (loss) from continuing operations per share	$ 57,615	$ (107,660)	$ (103,676)	$ (31,620)
Weighted average number of common shares outstanding (in shares)	371,721,382	349,075,408	367,391,118	348,946,439
Weighted average number of common shares for computation of diluted earnings (loss) from continuing operations per share (in shares)	375,349,856	349,075,408	367,391,118	348,946,439
Diluted earnings (loss) from continuing operations per share (in dollars per share)	$ 0.15	$ (0.31)	$ (0.28)	$ (0.09)
Loss from discontinued operations attributable to the shareholders of Cronos Group	$ (561)	$ (46)	$ (582)	$ (46)
Weighted average number of common shares for computation of diluted loss from discontinued operations per share (in shares)	375,349,856	349,075,408	367,391,118	348,946,439
Diluted earnings from discontinued operations per share (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Warrants
Diluted earnings (loss) per share computation
Dilutive effect of awards (in shares)	5,577	0	0	0
Stock options
Diluted earnings (loss) per share computation
Dilutive effect of awards (in shares)	3,027,518	0	0	0
Restricted share units
Diluted earnings (loss) per share computation
Dilutive effect of awards (in shares)	595,379	0	0	0

Earnings (Loss) Per Share - S_2

Earnings (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Shares Outstanding (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	116,862,709	162,091,326	128,373,444	162,158,002
Ginkgo equity milestones
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	14,674,904	14,674,904	14,674,904	14,674,904
Pre-emptive Rights
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	10,683,330	12,006,740	10,984,166	12,006,740
Top-up Rights – fixed price
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	3,698,611	26,686,413	7,406,031	26,686,413
Top-up Rights – market price
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	3,504,561	1,941,349	3,063,822	1,941,349
Altria Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	82,623,455	77,752,533	82,606,904	77,752,533
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	1,411,944	10,495,235	6,136,113	10,547,256
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	0	17,521,903	2,784,377	17,536,558
Restricted share units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities (in shares)	265,904	1,012,249	717,127	1,012,249

Segment Information - Narrative

Segment Information - Narrative (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)segment	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment			2
Current expected credit loss allowance on accounts receivable	$ 264,000		$ 264,000		$ 74,000
Loss from discontinued operations	(561,000)	$ (46,000)	(582,000)	$ (46,000)
Net revenue, before excise taxes	18,848,000	11,432,000	33,502,000	20,776,000
United States
Segment Reporting Information [Line Items]
Current expected credit loss allowance on accounts receivable	106,000		106,000		65,000
Loss from discontinued operations	0	0	0	0
Rest of World
Segment Reporting Information [Line Items]
Current expected credit loss allowance on accounts receivable	158,000		$ 158,000		$ 9,000
Four Major Customers | Rest of World
Segment Reporting Information [Line Items]
Net revenue, before excise taxes	$ 8,497,000			18,250,000
Customer Concentration Risk | Revenue Benchmark | Four Major Customers | Rest of World
Segment Reporting Information [Line Items]
Net revenue, before excise taxes		$ 7,040,000		$ 11,819,000
Concentration risk, percentage		71.00%		65.00%
Customer Concentration Risk | Revenue Benchmark | Ontario Cannabis Retail Corporation | Rest of World
Segment Reporting Information [Line Items]
Concentration risk, percentage	19.00%			15.00%
Customer Concentration Risk | Revenue Benchmark | Novolog Group | Rest of World
Segment Reporting Information [Line Items]
Concentration risk, percentage				14.00%
Customer Concentration Risk | Revenue Benchmark | Albert Gaming, Liquor and Cannabis Commission | Rest of World
Segment Reporting Information [Line Items]
Concentration risk, percentage	14.00%			12.00%
Customer Concentration Risk | Revenue Benchmark | Societe Quebecoise Du Cannabis | Rest of World
Segment Reporting Information [Line Items]
Concentration risk, percentage	12.00%			13.00%

Segment Information - Schedule

Segment Information - Schedule of Segment Data (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net revenue	$ 15,622	$ 9,883	$ 28,233	$ 18,315
Share of loss from equity accounted investments	1,115	794	2,758	1,966
Interest income	2,300	3,817	4,635	11,575
Interest expense	(7)	(83)	(13)	(90)
Interest income, net	2,293	3,734	4,622	11,485
Total assets	1,838,611	1,910,287	1,838,611	1,910,287	$ 1,925,682
Depreciation and amortization	1,043	679	1,778	1,366
Impairment loss on long-lived assets		40,000	1,741	40,000
Adjusted EBITDA	(49,759)	(26,986)	(86,333)	(64,041)
Purchase of property, plant and equipment, net	1,667	6,933	8,347	13,344
Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	2,227	2,174	4,668	4,350
Share of loss from equity accounted investments	0	0	0	0
Interest income	20	9	23	16
Interest expense	0	0	0	0
Interest income, net	20	9	23	16
Total assets	709,956	250,470	709,956	250,470
Depreciation and amortization	68	36	139	69
Impairment loss on long-lived assets		40,000	1,741	40,000
Adjusted EBITDA	(10,711)	(4,785)	(20,221)	(10,567)
Purchase of property, plant and equipment, net	239	39	319	219
Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	13,395	7,709	23,565	13,965
Share of loss from equity accounted investments	1,115	794	2,758	1,966
Interest income	2,280	3,808	4,612	11,559
Interest expense	(7)	(83)	(13)	(90)
Interest income, net	2,273	3,725	4,599	11,469
Total assets	386,805	348,569	386,805	348,569
Depreciation and amortization	975	643	1,639	1,297
Impairment loss on long-lived assets		0	0	0
Adjusted EBITDA	(32,605)	(18,618)	(54,789)	(47,628)
Purchase of property, plant and equipment, net	1,428	6,894	8,028	13,125
Corporate Expenses
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Share of loss from equity accounted investments	0	0	0	0
Interest income	0	0	0	0
Interest expense	0	0	0	0
Interest income, net	0	0	0	0
Total assets	741,850	1,311,248	741,850	1,311,248
Depreciation and amortization	0	0	0	0
Impairment loss on long-lived assets		0	0	0
Adjusted EBITDA	(6,443)	(3,583)	(11,323)	(5,846)
Purchase of property, plant and equipment, net	0	0	0	0
Cannabis flower
Segment Reporting Information [Line Items]
Net revenue	11,597	5,674	21,031	8,415
Cannabis flower | Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Cannabis flower | Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	11,597	5,674	21,031	8,415
Cannabis flower | Corporate Expenses
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Cannabis extracts
Segment Reporting Information [Line Items]
Net revenue	3,758	4,091	6,902	9,667
Cannabis extracts | Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	2,227	2,174	4,668	4,350
Cannabis extracts | Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	1,531	1,917	2,234	5,317
Cannabis extracts | Corporate Expenses
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Other
Segment Reporting Information [Line Items]
Net revenue	267	118	300	233
Other | Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Other | Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	267	118	300	233
Other | Corporate Expenses
Segment Reporting Information [Line Items]
Net revenue	$ 0	$ 0	$ 0	$ 0

Segment Information - Schedul_2

Segment Information - Schedule of Adjusted EBITDA (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting Information [Line Items]
Net income (loss)	$ 56,775,000	$ (107,703,000)	$ (104,850,000)	$ (32,022,000)
Interest income, net	(2,293,000)	(3,734,000)	(4,622,000)	(11,485,000)
Share of loss from equity accounted investments	1,115,000	794,000	2,758,000	1,966,000
Impairment loss on long-lived assets	0	40,000,000	1,741,000	40,000,000
Gain (loss) on revaluation of derivative liabilities	(115,248,000)	35,880,000	1,626,000	(77,488,000)
Transaction costs	2,758,000		3,259,000
Other, net	(1,127,000)	9,000	(911,000)	(785,000)
Loss from discontinued operations	561,000	46,000	582,000	46,000
Share-based payments	2,565,000	2,546,000	5,064,000	4,982,000
Review costs related to restatement of 2019 interim financial statements	1,932,000	3,459,000	3,937,000	7,866,000
Depreciation and amortization	3,203,000	1,717,000	5,083,000	2,879,000
Adjusted EBITDA	(49,759,000)	(26,986,000)	(86,333,000)	(64,041,000)
United States
Segment Reporting Information [Line Items]
Loss from discontinued operations	0	0	0	0
Operating Segments | United States
Segment Reporting Information [Line Items]
Net income (loss)	(11,719,000)	(45,566,000)	(23,811,000)	(52,082,000)
Interest income, net	(20,000)	(9,000)	(23,000)	(16,000)
Share of loss from equity accounted investments	0	0	0	0
Impairment loss on long-lived assets		40,000,000	1,741,000	40,000,000
Gain (loss) on revaluation of derivative liabilities	0	0	0	0
Transaction costs	0		0
Other, net	0	0	0	0
Loss from discontinued operations	0	0	0	0
Share-based payments	822,000	756,000	1,567,000	1,462,000
Review costs related to restatement of 2019 interim financial statements	0	0	0	0
Depreciation and amortization	206,000	34,000	305,000	69,000
Adjusted EBITDA	(10,711,000)	(4,785,000)	(20,221,000)	(10,567,000)
Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net income (loss)	79,627,000	(55,095,000)	(62,520,000)	33,772,000
Interest income, net	(2,273,000)	(3,725,000)	(4,599,000)	(11,469,000)
Share of loss from equity accounted investments	1,115,000	794,000	2,758,000	1,966,000
Impairment loss on long-lived assets		0	0	0
Gain (loss) on revaluation of derivative liabilities	(115,248,000)	35,880,000	1,626,000	(77,488,000)
Transaction costs	0		0
Other, net	(1,127,000)	9,000	(911,000)	(785,000)
Loss from discontinued operations	561,000	46,000	582,000	46,000
Share-based payments	1,743,000	1,790,000	3,497,000	3,520,000
Review costs related to restatement of 2019 interim financial statements	0	0	0	0
Depreciation and amortization	2,997,000	1,683,000	4,778,000	2,810,000
Adjusted EBITDA	(32,605,000)	(18,618,000)	(54,789,000)	(47,628,000)
Corporate Expenses
Segment Reporting Information [Line Items]
Net income (loss)	(11,133,000)	(7,042,000)	(18,519,000)	(13,712,000)
Interest income, net	0	0	0	0
Share of loss from equity accounted investments	0	0	0	0
Impairment loss on long-lived assets		0	0	0
Gain (loss) on revaluation of derivative liabilities	0	0	0	0
Transaction costs	2,758,000		3,259,000
Other, net	0	0	0	0
Loss from discontinued operations	0	0	0	0
Share-based payments	0	0	0	0
Review costs related to restatement of 2019 interim financial statements	1,932,000	3,459,000	3,937,000	7,866,000
Depreciation and amortization	0	0	0	0
Adjusted EBITDA	$ (6,443,000)	$ (3,583,000)	$ (11,323,000)	$ (5,846,000)

Segment Information - Schedul_3

Segment Information - Schedule of Revenue from External Customers by Geographic Areas (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 15,622	$ 9,883	$ 28,233	$ 18,315
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	10,664	7,416	18,246	13,507
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	2,227	2,174	4,668	4,350
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	2,310	293	4,828	293
Other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 421	$ 0	$ 491	$ 165

Segment Information - Schedul_4

Segment Information - Schedule of Long-lived Assets by Geographic Areas (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 193,920	$ 187,599
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	168,462	162,163
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	23,936	23,143
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 1,522	$ 2,293

Commitments and Contingencies (

Commitments and Contingencies (Details) - Pending Litigation $ in Millions	Jun. 16, 2020CAD ($)	Mar. 12, 2020shareholdercomplaint
Litigation Relating to Marketing, Distribution and Sale of Products
Loss Contingencies [Line Items]
Damages sought	$ 500
Punitive damages sought	$ 5
U.S. District Court of Eastern District of New York Vs. Cronos
Loss Contingencies [Line Items]
Number of alleged shareholders | shareholder		2
Number of putative class action complaints | complaint		2

Financial Instruments - Schedul

Financial Instruments - Schedule of Fair Value of Assets Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 895,181	$ 1,078,023
Short-term investments	201,699	211,766
Derivative liabilities	169,563	163,410
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	895,181	1,078,023
Short-term investments	201,699	211,766
Derivative liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Derivative liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Derivative liabilities	$ 169,563	$ 163,410

Financial Instruments - Credit

Financial Instruments - Credit Risk Narrative (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Concentration Risk [Line Items]
Maximum exposure to credit risk	$ 1,210,287	$ 1,403,491
Accounts receivable, threshold period past due, writeoff	120 days
Current expected credit loss allowance on accounts receivable	$ 264	$ 74
Accounts Receivable | Credit Concentration Risk | Four Customers
Concentration Risk [Line Items]
Concentration risk, percentage	74.00%	78.00%

Financial Instruments - Interes

Financial Instruments - Interest Rate Risk Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Investments, All Other Investments [Abstract]
Interest income, net	$ 2,293	$ 3,734	$ 4,622	$ 11,485

Financial Instruments - Liquidi

Financial Instruments - Liquidity Risk Narrative (Details) - Accounts Payable - Supplier Concentration Risk	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
One Vendor
Concentration Risk [Line Items]
Concentration risk, percentage	32.00%
Four Vendors
Concentration Risk [Line Items]
Concentration risk, percentage		64.00%

Financial Instruments - Currenc

Financial Instruments - Currency Rate Risk Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Risks and Uncertainties [Abstract]
Foreign exchange gain (loss) on translation	$ 13,470	$ 51,871	$ 29,754	$ (61,821)
Impact of ten percent change in exchange rate	$ 162,991		$ 162,991		$ 170,817

Held-For-Sale Assets and Disc_3

Held-For-Sale Assets and Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Write-down to held-for-sale assets			$ 1,039
Proceeds from sale of held-for-sale assets			2,059	$ 0
Discontinued Operations, Held-for-sale | OGBC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Write-down to held-for-sale assets	$ 561
Loss from discontinued operations, net of income taxes	(561)	$ (46)	(582)	$ (46)
OGBC assets classified as held-for-sale	645		$ 645		$ 1,176
Disposal Group, Held-for-sale, Not Discontinued Operations | OGBC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of held-for-sale assets	2,059
Gain on sale of property held-for-sale	$ 1,279

Impairment Loss on Long-Lived_2

Impairment Loss on Long-Lived Assets (Details) ft² in Thousands, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)ft²	Jun. 30, 2020USD ($)
Indefinite-lived Intangible Assets [Line Items]
Impairment of leasehold improvements to be disposed of		$ 1,039
Lessee, operating lease, area of land to be disposed of (in sqft) | ft²		6
Impairment charge on the de-recognition of the right-of-use asset		$ 702
United States
Indefinite-lived Intangible Assets [Line Items]
Goodwill, impairment loss	$ 35,000		$ 35,000
Lord Jones brand
Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets, indefinite-lived (excluding goodwill)	$ 5,000		$ 5,000